 
Official Title:  A Multicentre, Long -term Safety, Efficacy, and Pharmacokinetics 
Study of  Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 
Years with Functional Constipation  
Study ID: [REMOVED] 
Document  Date : Protocol Version 4 : 23-Nov-2015  
 
 
 
Sucampo AG  SAG/0211PFC -11S1-01 
 
 CONFIDENTIAL   16.1 Study Information  
 
Sucampo AG   SAG/0211PFC -11S1-01 
 
 CONFIDENTIAL   16.1.1  Final Amended Protocol and Protocol Amendment Summaries  
16.1. 1.1 Final Amended Protocol  
 
Sucampo AG   SAG/0211PFC -11S1  
 
 CONFIDENTIAL    
 
 
 
A Multicentre, Long -term Safety , Efficacy, and Pharmacokinetics  Study of 
Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years with 
Functional Constipation  
PROTOCOL NUMBER  SAG/0211PFC -11S1 
DRUG:  Lubiprostone  
SPONSOR:  Sucampo AG  
 Baarerstrasse 22, CH -6300, Zug, Switzerland  
  
  
Original Protocol Version and Date:  Version 1.0; 15 October 2013  
Protocol Version and Date:  Version 2.0; 26 November 2013  
 Version 3.0; 10 December 2013  
 Version 4.0; 19 November  2015  
  
Protocol Amendments:  Amendment 1; 26 November 2013  
 Amendment 2; 10 December 2013  
 Amendment 3; 19 November  2015  
 
   
 
CONFIDENTIALITY STATEMENT  
The information in this document may contain trade secrets or privileged information.  This document is classified 
as confidential and may not be disclosed, unless such disclosure is expressly permitted by [CONTACT_456017], Inc. or one of its subsidi aries (Sucampo AG, Sucampo Pharma Americas, LLC, Sucampo 
Pharma, Ltd., or Sucampo Pharma Europe, Ltd.) or unless disclosure is required by [CONTACT_774]. 
In any event, persons to whom you disclose the information must be informed by [CONTACT_10825] t hat this information is 
confidential and may not be further disclosed by [CONTACT_476] . These  restrictions on disclosure will apply equally to all future 
related information supplied to you, which is hereby [CONTACT_456018] l.

Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582854] INFORMATION  
 
US :  
Name  [INVESTIGATOR_124].  
Title  
Office/Mobile Telephone Number   
Office Fax Number   
After Hours Contact [CONTACT_19649]   
E-mail Address   
  
EU :  
Name   [CONTACT_28839], PhD, BBA   
Title  
Office   Telephone Number   
Office Fax Number   
After Hours Contact [CONTACT_19649]   
E-mail Address   
  
Sponsor Personnel:   
Name   
[CONTACT_456072]/Mobile Telephone  Number   
Office Fax Number   
E-mail Address    
  
Name   
[CONTACT_456072]/Mobile Telephone Number   
Office Fax Number   
E-mail Address    
  
Name   
[CONTACT_456072]/Mobile Telephone Number   
Office Fax Number   
E-mail Address    
  
  
24-hr IRE Reporting (Fax)   
  
 
If any contact [CONTACT_81416], written notification will be 
provided to the Investigator  and IRB/IEC , per requirements. A  protocol amendment  will not be 
required in this case.  

Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582855] read this protocol and discussed it with the Sponsor’s  representative. I agree to conduct 
this study in accordance with the protocol, International Conference on Harmonization  (ICH)  
Guideline on Good Clinical Practices and all applicable regulations.  
I will use only the informed consent documentation (ICD)  approved by [CONTACT_1636]/Independent Ethics Committee  (IRB/IEC) and Sponsor or its representative and will fulfil 
all responsibilities for submitting pertinent information to the IRB/IEC responsible for this study.  
I will provide copi[INVESTIGATOR_212625]. I will discuss this material with them to ensure 
they are fully informed regarding the drug and the conduct of the study.  
I agree that the Sponsor or its representatives shall have access to all original source 
documents, regardless of media, from which case report form (CRF) information may have 
been generated.  
I agree that all information regarding this protocol and lubiprostone will be  treated as strictly 
confidential. I further agree not to use the name [CONTACT_456073]. (SAG), the name [CONTACT_456074], the name [CONTACT_456075], or information relating to this protocol or 
any amendment hereto, in any publicity, news releas e, or other public announcement, written 
or oral, without the prior written consent of SAG.  
 
 
 
____________________________________________________  
Principal Investigator [CONTACT_25444]  
 
 
____________________________________________________  
Name [CONTACT_789] (Printed)      
 
 
____________________________________________________  
Institution         
 
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 20 15       Page 5 of 77 
   
TABLE OF CONTENTS  
PROTOCOL SIGNATURE P AGE  ..............................  ERROR! BOOKMARK NOT DEFINED.  
CONTACT [CONTACT_7533]  ................................ ................................ ................................ .... [ADDRESS_582856] AWAL OF SUBJECTS  ................................ ..................  24 
4.1 Inclusion Criteria  ................................ ................................ ................................ ...... 24 
4.2 Exclusion Criteria  ................................ ................................ ................................ ..... 24 
4.3 Reproductive Potential  ................................ ................................ .............................  25 
4.4 Contraception Specifications  ................................ ................................ ....................  25 
4.5 Withdrawal of Subjects  ................................ ................................ .............................  25 
4.6 Emergency Unblinding  ................................ ................................ .............................  26 
5. STUDY AND CONCOMITAN T TREATMENTS  ................................ ........................  27 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 20 15       Page 6 of 77 
 5.1 Study Medication Formulation  ................................ ................................ ..................  27 
5.2 Packaging  ................................ ................................ ................................ ................  27 
5.3 Labeling  ................................ ................................ ................................ ...................  27 
5.4 Storage and Handling ................................ ................................ ...............................  27 
5.5 Supply and Dosing  ................................ ................................ ................................ ... 28 
5.5.1  Reduction in Study Medication Dosing  ................................ ...............................  29 
5.5.2  Randomisation and Blinding  ................................ ................................ ..............  29 
5.5.3  Allocation of Study Medication  ................................ ................................ ...........  30 
5.6 Compliance and Drug Accountability  ................................ ................................ ........  30 
5.7 Concomitant Medications  ................................ ................................ .........................  30 
5.7.1  Excluded Medication  ................................ ................................ ..........................  30 
5.7.2  Daily Fibre Therapy ................................ ................................ ............................  31 
5.7.3  Rescue Medication  ................................ ................................ ............................  31 
6. STUDY PROCEDURES  ................................ ................................ ...........................  32 
6.1 Study Procedures by [CONTACT_4838]  ................................ ................................ ........................  32 
6.1.1  Completion of Study Procedures ................................ ................................ ........  32 
6.1.2  Enrolment Period – Visit 9 (Study Day 1)  ................................ ...........................  34 
6.1.3  Treatment Period  ................................ ................................ ...............................  35 
6.1.4  Follow -up Period  ................................ ................................ ................................  37 
6.1.5  Unscheduled Visit(s)  ................................ ................................ ..........................  38 
6.2 Efficacy Evaluations  ................................ ................................ ................................ . 38 
6.2.1  Electronic Diary  ................................ ................................ ................................ .. 38 
6.2.2  Efficacy Endpoints  ................................ ................................ .............................  38 
6.3 Safety Evaluations  ................................ ................................ ................................ ... 39 
6.3.1  Pharmacokinetic Evaluation  ................................ ................................ ...............  40 
7. ADVERSE AND SERIOUS ADVERSE EVENTS  ................................ ......................  41 
7.1 Definitions and Descriptions  ................................ ................................ .....................  41 
7.1.1  Serious Adverse Event  ................................ ................................ ......................  41 
7.1.2  Non-serious Adverse Event  ................................ ................................ ...............  42 
7.1.3  Severity  ................................ ................................ ................................ ..............  42 
7.1.4  Relationship to Study Medication  ................................ ................................ ....... 42 
7.1.5  Onset and Duration  ................................ ................................ ............................  42 
7.2 Recording and Reporting of Adverse Events  ................................ ............................  43 
7.2.1  Reporting of Immediately Reportable Events  ................................ .....................  43 
7.2.2  Outcome  ................................ ................................ ................................ ............  44 
7.2.3  Symptoms  of the disease under study  ................................ ...............................  44 
7.2.4  Clinical laboratory evaluations  ................................ ................................ ...........  44 
7.2.5  Vital Signs  ................................ ................................ ................................ ..........  45 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582857] Characteristics and Completion Status  ................................ ...... 46 
8.4 Analysis of Exposure to Study Medication, Rescue Medication, and 
Concomitant Medication  ................................ ................................ ...........................  46 
8.5 Analysis of Safety  ................................ ................................ ................................ ..... 47 
8.5.1  Deaths, Serious Adverse Events, and Adverse Terminations  ............................  47 
8.5.2  Adverse Events  ................................ ................................ ................................ .. 47 
8.5.3  Clinical Laboratory Tests  ................................ ................................ ...................  47 
8.5.4  Physical Examinations  ................................ ................................ .......................  48 
8.5.5  Bone Growth Assessments  ................................ ................................ ................  48 
8.5.6  Vital Signs  ................................ ................................ ................................ ..........  48 
8.5.7  Phar macokinetic Evaluations  ................................ ................................ .............  48 
8.5.8  Subgroup and Exploratory Analyses  ................................ ................................ .. 48 
8.6 Analysis of Efficacy  ................................ ................................ ................................ .. 48 
8.6.1  General Inferential Principles  ................................ ................................ .............  48 
8.6.2  Efficacy Endpoints  ................................ ................................ .............................  49 
8.7 Data Quality Assurance  ................................ ................................ ............................  51 
8.8 Data Collection  ................................ ................................ ................................ .........  52 
9. SPONS OR’S AND INVESTIGATO R’S RESPONSIBILITIES  ................................ .... 53 
9.1 Sponsor’s Responsibilities  ................................ ................................ .......................  53 
9.1.1  GCP Compliance  ................................ ................................ ...............................  53 
9.1.2  Regulatory Approval  ................................ ................................ ..........................  53 
9.1.3  Indemnity/liability and Insurance  ................................ ................................ ........  53 
9.1.4  Protocol Management  ................................ ................................ ........................  53 
9.1.5  End of Trial Notification  ................................ ................................ ......................  53 
9.1.6  Submission of Summary of Clinical Study Report to Competent Authorities 
of Concerned Member States and IECs  ................................ .............................  54 
9.2 Investigator’s Responsibilities  ................................ ................................ ..................  54 
9.2.1  GCP Compliance  ................................ ................................ ...............................  54 
9.2.2  Protocol Adherence and Investigator Agreement  ................................ ...............  55 
9.2.3  Documentatio n and Retention of Records  ................................ ..........................  55 
9.3 Ethical Considerations  ................................ ................................ ..............................  57 
9.3.1  Informed Consent  ................................ ................................ ..............................  57 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582858] OF FIGURES  
Figure 1:  Study Design Flow Chart  ................................ ................................ ...................  [ADDRESS_582859] OF APPENDICES  
Appendix 1  DIARY QUESTIONS (Children ≥6 to  18 Years of age)  ..........................  61 
Appendix 2  PEDIATRIC BLOOD PRESSURE LEVELS  ................................ .............  65 
Appendix 3  PEDIATRIC HEART RATE RANGES  ................................ ......................  69 
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 20 15       Page 9 of 77 
 ABBREVIATIONS AND DE FINITIONS  
ABPI  [INVESTIGATOR_455990] (SGPT)  
AST Aspartate Transaminase (SGOT)  
BID Twice Daily  
BM Bowel Movement  
BMC  Bone Mineral Content  
BMD  Bone Mineral Density  
BUN  Blood Urea Nitrogen  
bpm Beats Per Minute  
CFR Code of Federal Regulations  
cGMP  Current Good Manufacturing Practice  
CRF Case Report Form  
eCRF  Electronic Case Report Form  
CS Clinically Significant  
DSMB  Data Safety Monitoring Board  
DXA Dual-energy X -ray absorptiometry  
EDC  Electronic Data Capture  
EU European Union  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
GGT  Gamma -Glutamyl Transferase  
HIPAA  Health Insurance Portability and Accountability Act  
IBS Irritable Bowel Syndrome  
ICD Informed Consent Documentation  
ICH International Conference on Harmonisation  
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
IRE Immediately Reportable Event  
IXRS  Interactive Voice/Web Response System  
LAR Legally Authorised Representative  
LDH Lactose Dehydrogenase  
MAO  Monoamine Oxidase  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582860]  Medium Chain Fatty Acid Triglycerides  
MedDRA  Medical Dictionary for Regulatory Activities  
MHRA  Medicines and Healthcare products Regulatory Agency ([LOCATION_006])  
mITT Modified Intent -to-Treat  
NCS  Non-clinically Significant  
OTC  Over -the-Counter  
QD Once Daily  
PK Pharmacokinetics  
QoL Quality of Life  
RBC  Red Blood Cells  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SBM  Spontaneous Bowel Movement  
SNRI  Serotonin –Norepi[INVESTIGATOR_455991] -Specific Reuptake Inhibitor  
WBC  White Blood Cell  
WHO  World Health Organization  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 20 15       Page 11 of 77 
 PROTOCOL SYNOPSIS  
 
A Multicentre, Long -term Safety ,  Efficacy and Pharmacokinetics  Study of Lubiprostone in Paediatric 
Subjects Aged ≥6 to <18 years with Functional Constipation  
Study Phase  Phase 3  
Short Title  Long -term safety  extension study of lubiprostone for the treatment of paediatric 
functional constipation in subjects  aged ≥6 to <18 years   
Objectives, Study 
Medication and Dose 
Regimen:  To assess the long-term safety, efficacy, and pharmacokinetics of oral 
lubiprostone 12 or 24 mcg capsules dosed twice daily (BID) when administered 
orally for 36 weeks in paediatric sub jects with functional constipation.  
Evaluation of lubiprostone safety is the primary objective  in this study . 
 
Dose assignment will be based on the dose they were receiving at the time of 
rolling over from the preceding, double -blind study (SAG/0211PFC -1131) into 
this safety extension study  for those subject s who were randomised to receive 
lubiprostone during the preceding study . For subject s who received placebo 
during the preceding study, assignment o f dose will be assigned based on 
subject  body weight at the time of rollover to this extension study. All dose 
assignment will be handled by [CONTACT_288637]/Web Response system 
(IXRS) and will continue to maintain blinding with respect to the treatmen t 
assignment in the preceding trial.  
Assumed No. of Sites:  
Est. No. Enrolled 
Subjects:  
 
Est. No. Screened 
Subjects:  Approximately 130 (Northern America and E urope )  
[ADDRESS_582861] s who completed Study SAG/0211PFC -1131  
 
 
NA 
Duration of Participation:  
Duration of Treatment:  Up to 42 weeks (including follow -up)  
36 weeks  
Study Schedule:  
Visit 9 : Enrolment (Clinic Visit)  Day 1 (coincides with 
SAG/0211PFC -1131 study 
Visit 7)  
Visit 10:  Interim Treatment Visit ( Clinic 
Visit) Week 1 Visit (±2 days)  
Visit 11:  Telephone Assessment  Week 4 Visit (±3 days); 
Month 1  
Visit 12:  Interim Treatment Visit ( Clinic 
Visit) Week 12 Visit (±3 days); 
Month 3  
 Visit 13:  Telephone Assessment  Week 16 Visit (±3 days); 
Month 4  
Visit 14:  Interim Treatment Visit ( Clinic  
Visit) Week 24 Visit (±3 days); 
Month 6  
Visit 15:  Telephone Assessment  Week 28 Visit (±3 days); 
Month 7  
Visit 16:  End-of-Treatment (Clinic Visit)  Week 36 Visit (+3 days); 
Month 9  
Visit 17:  Follow -Up (Clinic Visit ) Week 40 Visit (+3 days); 
Month 10  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 20 15       Page 12 of 77 
 Inclusion Criteria:  
 
 1. Written informed consent obtained from subject and/or parent/legal 
guardian  (and assent from subject where applicable).  
2. Subject  must have completed the entire 12-week treatment period  from the 
preceding study (SAG/0211PFC -1131)  prior to enrol ment.   
3. Subject must continue to abstain from taking concomitant medication 
(prescribed or over -the-counter) that affects gastrointestinal motility; these 
medications include:  
a. Cholinesterase inhibitors; anti -spasmodic, anti -diarrheal, anti -
constipation, or prokinetic agents; laxative agents (e.g., PEG 3350), 
including homeopathic remedies;   
b. Tricyclic antidepressants; or  
c. Any medication, at the discretion of the Investigator, known to relieve 
or cause constipation or constipation -related symptoms, and which the 
Investigator, based on the medical history of the subject, suspects to 
be a contributing factor to the patient’s chronic constipation, or may 
otherwise confound the evaluation of treatment response . 
Exceptions:  Treatment with  antich olinergic agents, SSRIs, SNRIs, or 
MAO inhibitors is allowed if a stable dose has been used for at least 30 
days prior to the Baseline  Visit (of the preceding study SAG /0211PFC -
1131) and not likely to change during the study.  
4. Subject (and if necessary, parent /legal guardian ) must be willing and able 
to use or administer recommended (rectal and/or oral) rescue medications 
if needed.  
5. If subject is taking a fibre supplement (e.g., Metamucil®, PerDiem®, 
Fybogel), usage must have been at a stable dose not lik ely to change 
during the study.  
6. Subject and his/her parent/legal guardian must be willing and able to fill out 
his/her own diary.  
 
Exclusion Criteria:  
 
 
 1. Subject has current evidence of untreated faecal impaction.  
2. Subject  has experienced a n adverse event during the SAG/0211PFC -[ADDRESS_582862] ’s ability to participate in the trial.  
3. Subject  has had a significant change in their medical status, newly 
diagnosed and uncontrolled cardiovascular, liver or lung disease, 
neurologic or psychiatric disorder, or other systemic disease, which the 
Investigator considers to be  clinically significant and would limit the 
subject ’s ability to participate in the trial.  
4. Subject has developed abnormal laboratory test (haematology, urinalysis, 
or blood chemistry), which in the Investigator’s opi[INVESTIGATOR_455992], unexplained, and would limit the subject’s ability to participate 
in the trial.  
5. Subject (female of childbearing potential) has a positive pregnancy test , 
refuses/unwilling to undergo pregnancy testing , and/or does not agree to 
use protocol -specified  contraceptive measures  for the duration of the study . 
6. Subject  demonstrated non -compliance with study protocol (i.e., dosing 
schedule, visit schedule, diary completion, or study procedures) during the 
SAG/0211PFC -1131 study . 
 
Rescue Treatment  In the event that no bowel movement  (BM) has occurred within a 3 -day period, 
the use of recommended rescue medications may be allowed per Investigator’s 
instructions. Recommended rescue medications include bisacodyl, senna, 
sodium pi[INVESTIGATOR_31320], and saline enemas.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 20 15       Page 13 of 77 
 Safety E ndpoint s: The safety endpoints are as follows:  
 Incidence of adverse events  (AEs)  grouped by [CONTACT_141588] (SOC) and Preferred Term  
 Changes from baseline in clinical laboratory parameters (haematology, 
serum chemistry, urinalysis)   
 Changes from baseline in ph ysical examination   
 Changes from baseline in vital sign measurements, including height and 
weight  
o Height will be measured using a wall -mounted stadiometer , if 
available   
 For those subjects who were aged 6 to 9 or 14 to 17 at the time of enrolment 
into the  SAG/0211PFC -1131 study, and who were qualified to participate 
and enrolled in the d ual-energy X -ray absorptiometry  (DXA) substudy:  
o Percent changes from baseline in bone mineral density (BMD) and 
bone mineral content (BMC ) 
o Changes from baseline in BMD Z -scores and in height -adjusted Z -
scores, as assessed by [CONTACT_456019]  
o Changes from baseline in height  and weight Z -scores for DXA 
Subgroup  
o Incidence of clinical fractures  
 
A Data Safety Monitoring Board (DSMB) will monitor safety data on a regular 
basis throughout the study. Specifics, including meeting frequency and 
stoppage criteria, are provided in the DSMB Charter.  
Efficacy Endpoints:  The efficacy endpoints are as follows:  
 Overall and monthly change s from baseline in BM and SBM frequency 
rate 
 Overall  and monthly assessments of the average degree of , and changes 
from baseline in:  
o Stool consistency of SBMs  
o Straining associated with SBMs  
o Abdominal pain  associated with SBMs  
o Constipation severity  
 Monthly SBM Response  
o A monthly  responder is defined as a subject who is a weekly responder 
for [ADDRESS_582863] who has a frequency rate 
of ≥ 3 SBMs/week and an i ncrease from baseline of ≥ 1 SBM/week for 
that week.  
 Overall and monthly assessment of average tre atment effectiveness  
rating  
 Overall Health -related quality of life (PedsQL™)  
 Overall and monthly c hange from baseline in incontinence epi[INVESTIGATOR_455993] (analysis performed for subset of subjects presenting with 
incontinence at baseline)  
 Overall and monthly c hange  from baseline in the production of large 
diameter stool (a stool that clog s the toilet) frequency  
 Overall and monthly c hange from baseline in frequency of faecal 
impaction  
 Overall and monthly c hange from baseline in p roportion of BMs and SBMs 
in toilet  overall  
 Overall and monthly c hange from baseline in frequency of retentive 
posturing or excessive volitional stool retention  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 20 15       Page 14 of 77 
  
Pharmacokinetic 
Evaluation:  Plasma samples will be collected for population pharmacokinetic (PK) modeling 
at Visit 9 as follows:  
 Pre-dose and 1 sample between 30 and 90 minutes after dose 
administration (2 samples total)  
A population PK analysis will be performed using the concentration -time data 
from the sparse PK samples in this study. The analysis may include data from 
other studies with lubiprostone in adults, paediatric subjects , or healthy 
volunteers. A separate anal ysis plan for the population PK analysis will be 
prepared prior to database lock.  
Sample Size Estimate 
Calculation  For purposes of establishing the safety profile with lubiprostone long -term 
exposure in p aediatric functional constipation, safety data from  subjects 
enrolled in this study will be considered together with the 100 subjects enrolled 
in Sucampo study SAG/0211PFC -11S2  (subjects in this study will be below 6 
years old) . 
 
The sample size is based on the expected attrition that would occur and the 
remaining number of safety evaluable subjects at each timeframe  during the 
study . 
Statistical Methodology  Efficacy analysis will be based on modified intent -to-treat ( mITT) population 
which includes all enrolled subjects who take at least one dose of study  
medication  and have at least one treatment period diary entry . Categorical and 
discrete variables will be summarized by [CONTACT_456020], and 
continuous  variables will be summarized by [CONTACT_9086]. Detailed 
statistical methodology will be documented in the Statistical Analysis Plan  
(SAP) . 
 
Adverse events will be summarized in terms of incidence by [CONTACT_259000]. Changes from baseline or clinical abnormalities in clinical 
laboratory data, physical examinations, and vital signs will be summarized by 
[CONTACT_2938].  
 
The PK profile for lubiprostone will be determined from the concentration -time 
data for all evaluable subjects based on the plasma concentrations lubiprostone 
(if measurable) and of lubiprostone’s metabol ite, M3. Actual post -dose sampling 
times relative to time of study medication administration, rather than scheduled 
sampling times, will be used in all PK profile computations involving sampling 
times.  
 
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015         Page 16 of 77 
 4 PK samples will be collected predose and 1 sample between 30 and 90 minutes after dose administration (2 samples total). PK s amples wil l be taken under non -fasting conditions. The 
samples will be collected via direct venipuncture . Approximately 8 mL of blood will be taken for each sample such that the total of all PK samples does not exceed 50 mL or 5 mL/kg of body 
weight;  
5 Urine pregnancy tests will be performed at all study visits on subjects of childbearing potential.  
6 All subjects who withdraw from the study after Visit 12 (Month 3 ) should complete the final visit of the treatment period (Visit 16) and therefore have a final D XA assessment performed . This 
will only be required for subjects that were originally part of the DXA subgroup . Any subject demonstrating a decline in 4% in BMD at any skeletal site from Screening to End of Treatment 
should additionally undergo a follow -up DXA assessment  6 to 12 months later ;  
[ADDRESS_582864] or parent/legal guardian as he/she administers the first dose of study medication while in the clinic at Visit 9. Over the next [ADDRESS_582865] will be instructed to take the study medication only from the newly dispensed bottle;  
8 Change e Diary mode to new treatment mode (associated with current study - SAG/0211PFC -11S1)  at Visit 9.  
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 17 of 77 
 1. INTRODUCTION  
1.1 Disease Overview  
Constipation in children has similar characteristics to that of constipation in adults in that 
symptoms include infrequent bowel movements ( BMs), hard stools, and painful passage of 
stools. Children may also experience faecal  retention due to withholding .1,2 There is a tendency 
to avoid defecation and withhold BMs due to  pain experienced from the passage of large 
stools. This withholding of BMs can result in epi[INVESTIGATOR_455994]. Functional 
constipation occurs in all paediatric age groups, from n ewborns to young adults and its severity 
may vary from mild and short -lived to severe and chronic with faecal impaction.  It is responsible 
for 3 –5% of paediatric  outpatient visits and 25% of paediatric  gastroenterology 
consultations .1,2,[ADDRESS_582866] 4 years with insufficient criteria for diagnosis of  irritable bowel 
syndrome  (IBS) present with two or more of the following at least once per week for 2 months 
prior to diagnosis:  
• Two or fewer defecations in the toilet per week  
• At least one epi[INVESTIGATOR_455995]  
• History of retentive posturing or excessive volitional stool retention  
• History of painful or hard bowel movements  
• Presence of a large faecal mass in the rectum  
• History of large diameter stools which m ay obstruct the toilet  
One systematic review showed a worldwide prevalence of childhood constipation in the 
general population ranging from 0.7% to 29.6%.[ADDRESS_582867] a family history of constipation.7  Another follow -up study assessing the 
clinical course of severe functional con stipation in early childhood found that after initial 
success of treatment, a relapse occurred in 15% of the children within [ADDRESS_582868] in other therapeutic 
strategies .9 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582869] Background  
Lubiprostone (24 -mcg capsules admi nistered twice daily [BID]) is currently approved in the US 
under the trade name [CONTACT_456076]® for the treatment of adults with chronic idiopathic constipation  
and opi[INVESTIGATOR_2480] -induced constipation in adults with chronic, non -cancer pain , and for women with 
irritable  bowel syndrome with constipation (8 mcg BID) . Lubiprostone 24 -mcg BID is also 
approved for treatment of adult chronic idiopathic constipation in the [LOCATION_008] and 
Switzerland. Lubiprostone was approved for marketing in Japan on 29 June 2012 for the 
treatment of chronic constipation (excluding constipation caused by [CONTACT_456021])  in the 
adult population. In several well -controlled cli nical studies in subjects with chronic idiopathic 
constipation , opi[INVESTIGATOR_2480] -induced constipation  or irritable bowel syndr ome with constipation, 
lubiprostone  has been shown to increase the frequency of spontaneous bowel movements 
(SBMs ) in adults , to improve stool consistency, and to reduce straining, abdominal bloating, 
and abdominal discomfort .10 An open -label safety and ef ficacy study of 4 weeks’ duration ha s 
also been conducted in p aediatric functional constipation subject s aged 3 -17 years who were 
treated with lubiprostone  12 mcg once daily ( QD), [ADDRESS_582870] in other 
therapeutic strategies . Since lubiprostone has been shown to increase the frequency of SBMs  
in both adults and children, further evaluation in well controlled studies in children is  needed 
to demonstrate use in a paediatric population.  The doses selected for this study are based on 
the results obtained during the previous open -labeled study in children.12 Highly statistically 
significant (p<0.0001) changes from baseline SBM frequency  at Week 1 were observed overall 
for children  treated with lubiprostone, with children  treated with either lubiprostone 12 mcg BID 
or 24 mcg BID achieving a mean SBM frequency of > [ADDRESS_582871] provided some additional treatment 
benefit s. 
Subjects who  completed the entire 12 -week treatment in the preceding double -blind study 
(SAG/0211PFC -1131)  will be eligible to enrol into this long-term safety study. Dose assignment 
will be based on the dose they were receiving at the time of rolling over from the previous  study 
into this safety extension study  for those subject s who were randomi sed to receive lubiprostone 
during the preceding study. For subject s who received placebo during the preceding study, 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582872]  body  weight at the time of rollover to 
this extension study. All dose assignment will be handled by [CONTACT_288637]/Web 
Response system (IXRS) and will continue to maintain blinding with respect to the treatment 
assignment in the preceding trial . 
Lubipros tone has a well -documented safety record in clinical studies involving over 3,[ADDRESS_582873], along with previously observed improvement in constipation signs 
and symptoms in both children and adults, provides a potential treatment option in a paediatric 
population . 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 20 of 77 
 2. STUDY OBJECTIVES AND  ENDPOINTS  
2.1 Objectives  
To assess the long -term safety, efficacy, and pharmacokinetics of oral lubiprostone 12 or 24 
mcg capsules dosed twice daily (BID) when administered orally for 36 weeks in paediatric 
subjects with functional constipation.  Evaluation of lubiprostone safety is the primary objective  
in this study . 
2.2 Endpoints  
2.2.1  Safety  
The safety endpoints are as follows:  
 Incidence of adverse events grouped by [CONTACT_7204]  (SOC) and 
Preferred Term   
 Changes from baseline in clinical laboratory parameters (haematology, serum chemistry, 
urinalysis)  
 Changes from baseline in physical examination  
 Changes from baseline in v ital sign  measurement , including height, and weight   
o Height will be measured using a wall -mounted stadiometer , if available   
 For those subjects who were aged 6 to 9 or 14 to 17 at the  time of enrolment  into the 
SAG/0211PFC -1131 study, and who were qualified to participate and enrolled in the DXA 
substud y: 
o Percent changes from baseline in BMD and BMC  
o Changes from baseline in BMD Z -scores and in height -adjusted Z -scores, as 
assessed by D XA for DXA Subgroup  
o Changes from baseline in height and weight Z -scores  
o Incidence of  clinical fractures   
 
A DSMB  will monitor safety data on a regular basis throughout the study. Specifics, including 
meeting frequency and stoppage criteria, are provided in  the DSMB  Charter.  
2.2.2  Efficacy  
The efficacy endpoints are as follows:  
 Overall and monthly change s from baseline in BM and SBM frequency rate 
 Overall and monthly assessments of the average degree of, and changes from baseline 
in: 
o Stool consistency of SBMs  
o Straining associated with SBMs  
o Abdominal pain  associated with SBMs  
o Constipation severity  
 Monthly SBM Response  
o A monthly responder is defined as a subject who is a weekly responder for 3 of 4 
weeks per month.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582874] who h as a frequency rate of ≥ 3 
SBMs/week and an increase from baseline of ≥ 1 SBM/week for that week.  
 Overall and monthly assessment of average treatment effectiveness rating  
 Overall Health -related quality of life (PedsQL™)  
 Overall and monthly change  from baseline in incontinence epi[INVESTIGATOR_455996]  (analysis 
performed for subset of subjects presenting with incontinence at baseline)  
 Overall and monthly change  from baseline in the production of large diameter stool (a 
stool that clogs the toilet) frequ ency  
 Overall and monthly change from baseline  in frequency of faecal impaction  
 Overall and monthly change from baseline  in proportion of BMs and SBMs in toilet overall  
 Overall and monthly change from baseline in frequency of retentive posturing or 
excessive volitional stool retention  
[IP_ADDRESS]  Patient Reported Outcomes  
Hand -held electronic diaries will be utilized to collect daily responses to questions involving 
bowel habit symptoms, study drug administration, and rescue medication  administration (see 
Appendix 1). 
 
The PedsQL™ Generic Core Scales13 will be completed by [CONTACT_456022]/legal guardian  
via paper questionnaires  at Visit 9, Visit 12, Visit 14 and Visit 16. 
2.2.3  Pharmacokinetics  
Plasma samples will be collected for population PK modeling at Visit 9 as follows:  
 Pre-dose and 1 sample between 30 and 90 minutes after dose administration (2 samples 
total)  
A population PK analysis will be performed using the concentration -time data from  the sparse 
PK samples in this study. The analysis may include data from other studies with lubiprostone 
in adults, paediatric subject s, or healthy volunteers. A separate analysis plan for the population 
pharmacokinetic analysis will be prepared prior to d atabase lock.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582875] visits  or periods  during  the study:  
 
 Enrolment  Visit (Visit 9; Day 1): This visit is considered study Day [ADDRESS_582876] day of study medication administration  and will coincide with Visit 7  of 
the preceding study SAG/0211PFC -1131 .   
 
 Interim Treatment Clinic Examinations ( Visits 10, 12, 14; Weeks  1, 12, 24 ) and End -
of-Treatment Visit (Week 36): A clinic visit will occur on Study Days 8 (±2 days ), 85 (±3 
days ), 169 (±3 days)  and 253 (±3 days ). Clinical assessment s will be performed to 
evaluate the safety of study treatment.  
 Interim Telephone Assessments (Visit s 11, 13, and 15; Week s 4, 16, and 28 ): A 
telephone assessment will be performed by [CONTACT_456023] 29  (±3 days ), 
113 (±3 days ), and 197  (±3 days ). This assessment will be performed to evaluate the 
compliance of the subject with the study medication and electronic diary and to identify 
any adverse events (AEs) or changes in concomitant medications.  
 
 Follow -up Visit  (Visit 17; Week 40 [Day 281  + 3 days ]): A follow -up clinic  visit will occur 
to review any ongoing or new onset of AEs, record any cha nges in concomitant 
medications . The subject’s overall condition will be assessed; and blood and urine will 
be co llected for laboratory analyses . This will conclude the subject’s involvem ent in the 
study.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582877] satisfy the following criteria before entering the study:  
 
1. Written informed consent obtained from subject or parent /legal guardian  (and assent 
from subject where applicable).  
2. Subject must have completed the entire 12-week treatment period during the preceding 
study ( SAG/0211PFC -1131 ).  
3. Subject must continue to abstain from taking concomitant medication (prescribed or 
over-the-counter) that affects gastrointestinal motility; these medications include:  
a. Cholinesterase inhibitors; anti -spasmodic, anti -diarrheal, anti -constipation, or 
prokinetic agents; laxative agents (e.g., PEG 3350), including homeopathic 
remedies;  
b. Tricyclic antidepressants; or  
c. Any medication, at the discretion of the Investigator, known to relieve or cause 
constipation or constipation -related symptoms, and which the Investigator, based 
on the medical history of the subject, suspects to be a contributing factor to the 
patient’s chron ic constipation, or may otherwise confound the evaluation of 
treatment response . 
Exceptions:  Treatment with anticholinergic agents, SSRIs, SNRIs, or MAO inhibitors 
is allowed if a stable dose has been used for at least 30 days prior to the Baseline  Visit 
(of the preceding study SAG /0211PFC -1131) and not likely to change during the study.  
4. Subject (and if necessary, parent /legal guardian ) must be willing and able to use or 
administer recommended (rectal and/or oral) rescue medications if needed.  
5. If subject is  taking a fibre supplement (e.g., Metamucil®, PerDiem®, Fybogel), usage 
must have been at a stable dose not likely to change during the study.  
6. Subject and his/her parent/legal guardian must be willing and able to fill out his/her own 
diary.  
4.2 Exclusion Criteria  
Subjects who meet any of the following criteria will be excluded from participating in the 
study:  
 
1. Subject has current evidence of untreated faecal impaction.  
2. Subject  has experienced a n adverse event during the SAG/0211PFC -[ADDRESS_582878] ’s ability to 
participate in the trial.  
3. Subject  has had a significant change in their medical status, newly diagnosed and 
uncontrolled cardiovascular, liver or lung disease, neurol ogic or psychiatric disorder, or 
other systemic disease, which the Investigator considers to be  clinically significant and 
would limit the subject ’s ability to participate in the trial.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582879] (haematology, urinal ysis, or blood 
chemistry), which in the Investigator’s opi[INVESTIGATOR_455997] ’s ability to participate in the trial . 
5. Subject (female of childbearing potential) has a positive pregnancy test , refuses/ is 
unwilling to un dergo pregnancy testing , and/or does not agree to use protocol -specified  
contraceptive measures for the duration of the study . 
6. Subject  demonstrated non -compliance with study protocol (i.e., dosing schedule, visit 
schedule, diary completion, or study procedures) during the SAG/0211PFC -[ADDRESS_582880] 
shall be recorded in the source document . Adequate contraception is defined as use of any of 
the following:  
 Oral Contraceptive – must have been used for at least 3 months prior to the Screening 
Visit (Visit 1) ; 
 Intrauterine Device (IUD) ; or 
 Double barrier method . 
4.[ADDRESS_582881]’s medical record and on the withdrawal form in the 
electro nic Case Report Form ( eCRF).  
Subject participation may be terminated prior to completion of the clinical study for any of the 
following reasons:  
 
 AE;  
 Lack of efficacy ;  
 Subject choice;  
 Lost to follow -up;  
 Non-compliance;  
 Investigator decision;  
 Sponsor request; or  
 Any other reason upon agreement between the Investigator and the Sponsor.  
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 26 of 77 
 Subjects who withdraw from the study early or who are terminated from the study should 
complete the final visit of the treatment period (Visit 16) as outlined in Section [IP_ADDRESS]  and the 
Follow -up Visit (Visit 17) as outlined in Section [IP_ADDRESS] . All subjects who withdraw from the 
study after Visit 12 (Month 3) should have a final DXA assessment performed.  This will only 
be required for subjects that were originally part of the DXA subgroup . 
 
When a subject withdraws prior to completing  the study, the reason for withdrawal shall be 
documented in the source documents and on the appropriate  eCRF page . In any case where 
the action taken with study medication is listed as permanently withdrawn due to an adverse 
event, the reason selected for  withdrawal in the eCRF must be “AE” (i.e., Investigator decision 
or other category should not be selected in such cases).  
Attempts should be made to locate subjects who are lost to follow -up so that as much study 
information as possible may be obtained. Every effort should be made to retrieve dispensed 
study medication, electronic diaries, and obtain the general overall status of the subject at the 
time of withdrawal from the study. The subject’s source documents should verify that at least 
two attempts h ave been made by [CONTACT_456024] a final attempt to 
locate the subject has been made by [CONTACT_456025].  
4.[ADDRESS_582882] 50 kg in weight  at the time 
of randomisation in the preceding study (SAG/0211PFC -1131) . In the event emergency 
unblinding of study dose  is necessary, the Investigator shall utilize the RTSM system  to obtain 
subject dose details . The individual subject dose details should  be revealed only in case of an 
emergency where the further treatment of the subject is dependent on knowing the actual dose  
he or she has received.  
 
It is strongly encouraged that unblinding only be completed after consultation with  the study 
medical moni tor and/or Sponsor , provided this does not compromise subject  safety. If 
unblinding should occur (either by [CONTACT_456026] a medical emergency), the Investigator must 
promptly and immediately notify the Sponsor, study medical monitor, and  IRB/IEC , and 
document the circumstances surrounding this action in a memorandum to the study file.    
 
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 27 of 77 
 5. STUDY AND CONCOMITAN T TREATMENTS  
5.1 Study Medication Formulation  
Lubiprostone drug substance is white, odo urless crystals or crystalline powder and is v ery 
soluble in ether and ethanol, and practically insoluble in hexane and water. Lubiprostone is 
available for oral administration in a soft gelatin capsule formulation. Each soft gelatin capsule 
is filled with lubiprostone dissolved in medium chain fatty acid triglycerides (MCT)  solution . 
Lubiprostone is the sole active ingredient. Each capsule contains [ADDRESS_582883] or monitoring of the study, 
will label, package, and di stribute study medication. Study medication labe ling will be provided 
in accordance with current Good Manufacturing Practice  (cGMP ) requirements and local 
regulatory specifications and requirements.  The study medication will be packaged in bottles 
with a child -resistant cap. Each bottle will contain a 4 -week supply plus a 4-day overage (6 4 
capsules) of study medication (lubiprostone 12- or 24 -mcg capsules).  
5.[ADDRESS_582884]  will b e label ed with a minimum of the  following information:  
 Protocol Number;   
 Bottle Number (if applicable);   
 Dosage form (including pro duct name);  
 Manufacturing and storage information ;  
 Directions for use, storage conditions, expi[INVESTIGATOR_455998] e (if applicable), batch number;   
 The statements ‘For clinical trial use only’, and/or ‘CAUTION: New Drug - Limited by 
[CONTACT_4496] (United Stat es) Law to Investigational Use’,  or the equivalent texts outside [LOCATION_003], 
as applicable;   
 The Sponsor's name [CONTACT_3816];   
 Any additional la beling requirements for participating countries and/or controlled 
substances wil l also be included on the label;   
 Subject Number (To be written by [CONTACT_779]) ; 
 Subject Initials (To be written by [CONTACT_779] , where applicable ); 
 Dispense Date (To be written by [CONTACT_779]) . 
5.[ADDRESS_582885] . The medication will be stored at room temperature, 
defined as thermostatically -controlled to normal working environment of 20°C (68°F) to 25°C 
(77°F); excursions between 15ºC and 30ºC (59ºC to 86ºF) are allowed. Limited responsibility 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582886] of the preceding double -blinded study (SAG/0211PFC -1131), bottles will not 
specifically identify whether they contain lubiprostone [ADDRESS_582887] o f two (2) doses 
of study medication, one (1) capsule per dose  in the morning and in the evening . If a dose is 
missed, the subject should take the missing dose as soon as possible, but should not “double 
up” doses, i.e., take [ADDRESS_582888] and his/her parent/legal guardian will be instructed to administer  study medication  
with meals  and at least 8 ounces  (240 mL)  of fluid. All doses should be taken at least 5 hours 
apart. The parent/legal guardian  should record the actual time the dose w as taken in the 
electronic diary. If the dose was missed entirely, the parent/legal guardian  should indicate the 
omission in the electronic diary as instructed. The study medication will be handled by 
[CONTACT_456027] n of the Investigator or designated 
site personnel.  
Each subject will receive one 64-capsule bottle  of study medication at the Enrolment  Visit (Day 
1), and three bottles each at Visits 10, 12, and 14. The first dose of study medication will be 
administered in the clinic at the Enrolment Visit and the Study Coordinator will record this first 
dose.  
 
Subjects should return the used bottle of study medication at each clinic visit for collection by 
[CONTACT_456028]. If the study medication is not returned, the bottle of all unused study 
medication should be returned to the site a t the subsequent office visit. The subject will be 
instructed to take the study medication only from the newly dispe nsed bottle . The last dose of 
study medication in this study  will be taken on the day of End of Treatment (Visit 16) . 
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582889] to the site and has been ongoing for three or more days : 
 
 Nausea  – In cases where the subject is experiencing severe nausea, the Investigator 
may reduce the study medication to  once daily  (QD) dosing at their discretion and in 
consultation  with the subject.  
 Diarrhea  – In cases where the subject is experiencing severe diarrhea, the Investigator 
may reduce the study medication to QD dosing at their discretion and in consultation 
with the subject.  
 Other  – In cases where the subject is experien cing some other type of AE, the 
Investigator may reduce the study medication to QD dosing upon consultation with and 
approval of the medical monitor.  
 
Once the adverse event is reported by [CONTACT_423], site personnel should follow the subject for 
any chang e in the nature of the event. If the event has not resolved after [ADDRESS_582890] 
may resume administration of the BID dose regimen per Investigator discretion.  
Note: Investigators should assess the need for reduction of the study medication at 
each visit.  
5.5.[ADDRESS_582891] of the preceding double -
blinded study (SAG/0211PFC -1131), bottles will not specifically identify whether they contain 
lubiprostone 12 or 24 mcg so as to maintain the prior blind.  Dose assignment will be based on 
the dose they were receiving at the time of rolling over from the preceding, double -blind study 
(SAG/0211PFC -1131) into this safety extension study for those subjects who were randomi sed 
to receive lubiprostone during the preceding study. For subjects who r eceived placebo  during 
the preceding study  (as identified via IXRS) , assignment of dose by [CONTACT_456029].  Dose assignment will only 
be known in subjects who were at least 50 kg  in weight at the time of randomisation in the 
preceding study (SAG/0211PFC -1131). All dose assignment s will be handled by [CONTACT_456030]. 
Most study  personnel  will remain blinded to doses assigned to subjects weighing less than 50 
kg until the clinical database has been locked. To allow for the execution of clinical trial –related 
services, the following individuals will be unblinded during the study : 
 External RTSM  vendor  
 Sponsor Quality Assurance representative  
 Sponsor Pharmacovigilance representative  
 External c linical supply distribution vendor  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 30 of 77 
  External third party u nblinded biostatistician (e.g., DSMB statistician)  
 DSMB members  
 Bioanalytical laboratory and third-party pharmacokinetic analyst  
 Sponsor Drug Supply Management representative  
Emergency unblinding by [CONTACT_276988] a subject’s assigned treatment is addressed in 
Section 4.[ADDRESS_582892] identifier (“xxxx -yyy”)  that was assigned in the 
preceding double -blind study ( SAG/0211PFC -1131 ). This subject ID number will also be used 
as a unique identifier for the subject throughout the study for lab reports, diary, study 
medication labels, eCRFs, etc.  
5.[ADDRESS_582893]’s eCRF.  See Section 5.5 for instructions about return of 
study medication.  Study medication returned by [CONTACT_456031]’s instructions. Contents of the study medi cation bottles must not be 
combined.  
Designated study personnel will maintain a log of all study medications dispensed and 
returned. The Sponsor or designee will verify the drug accountability log during on -site 
monitoring visits. Study medication supplie s for each subject will be inventoried and accounted 
for throughout the study. Study medication administration will be documented in the source 
documentation, including dispensation information and capsule counts, and entered in the 
appropriate eCRF page. Study medication dosing will also be recorded by [CONTACT_456032]/legal guardian  in the electronic diaries . 
5.[ADDRESS_582894] week following the End-of-
Treatment Visit : 
 Anti-spasmodics;  
 Cholinesterase inhibitors;  
 Anti-diarrheal medications;  
 Anti-constipation medications  (e.g., Linzess ™/ Constella ™, Relistor®, or Resolor®);  
 Prokinetic agents;  
 Laxative agents  (e.g., PEG 3350) , including homeopathic remedies;  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 31 of 77 
  Tricyclic antidepressants;  
 Any medications at the discretion of the Investigator known to relieve or cause 
constipation or constipation symptoms , and which the Investi gator, based on the medical 
history of the subject, suspects to be a contributing factor to the patient’s chronic 
constipation, or may otherwise confound the evaluation of treatment response . 
 
Exceptions:  Treatment with anticholinergic agents, SSRIs, SNRIs , or MAO inhibitors is 
allowed if a stable dose has been used for at least 30 days prior to the Baseline  Visit (of the 
preceding study S AG/0211PFC -1131) and not likely to change during the  study.  
 
These medications should be documented as concomitant medic ations.  The Sponsor (medical 
monitor) must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_368742]. Continued participation of the subject will be at the 
discretion of the Sponsor.  
5.7.[ADDRESS_582895] 30 days prior to the Baseline  Visit (of the preceding study 
SAG/0211PFC -1131) . The schedule of u sage and dose of the daily fibre  supplement should 
not change during th e course of the study. Any fibre  supplement used should be documented 
as a concomitant medication.  
5.7.3  Rescue Medication  
If necessary, rescue medication may be used to help induce a BM. The use of approved rescue 
medicati ons is outlined below. Each parent/legal guardian  should be educated on the protocol -
specified use of rescue medications at the Enrolment  Visit (Visit 9) and throughout the study.  
In the event that no BM has occurred within a 3 -day period, the use of rescue medications is 
permitted per the Investigator’s instructions  as described below.  
 
a. Rescue medication 1 : The subject  or parent/legal guardian  administer the clinically 
recommended  dose  of bisacodyl, senna, or sodium pi[INVESTIGATOR_31320] . 
b. Rescue medication 2 : If the first rescue medication fails to induce a bowel 
movement, the subject  or parent/legal guardian  may administer a repeat dose of 
bisacodyl, senna, sodium pi[INVESTIGATOR_207489], or administer a saline enema .  
c. If both rescue medications fail, the subject or parent/legal guardian may contact [CONTACT_456033] -term use . The recommendation  may include a medicatio n from the excluded 
medication list other than  any form of polyethylene glycol (PEG) , Linzess™/  
Constella™, Relistor®, or Resolor® (Section 5.7.1 ), all of which are considered 
prohibited rescue medications .  
 
Should the use of rescue therapy be necessary, it will be recorded in the electronic diary by 
[CONTACT_456022] /legal guardi an, and  recorded on the  Rescue Medication eCRF page . 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582896] dose of study medication.  
 
Subjects are expecte d to comp lete all study periods . Subjects who withdraw from the study 
early or who are terminated from the study should complete the final visit of the treatment 
period (Visit 16) and the follow -up visit (Visit 17). All subjects who withdraw from the study after 
Visit 12 (Month 3) should have a final DXA assessment performed.  This will only be required 
for subjects that were originally part of the DXA subgroup . All visits are outlined in this section.  
 
The details of the procedures for the Enrolment  Visit and subse quent visits as specified are 
below.  
 
Medical History – An updated medical history of the subject  will be recorded. Particular 
attention should be made regarding the subject ’s continued status of functional constipation  
and related symptoms .  
 
Inclusion/Exclusion – The subject will be assessed to determine their eligibility for the study 
based upon the inclusion ( Section 4.1) and exclusion ( Section 4.2) criteria.   
 
Height  – The subject’s height will be recorded using a wall -mounted stadiometer , where 
available,  in inches or centimeters. Alternate methods and further guidance will be provided in 
a study manual.  
 
Weight  – The subject’s weight will be recorded in pounds or kilograms.  
 
Vital Signs  – The subject ’s blood pressure, heart rate, respi[INVESTIGATOR_697], and temperature will 
be recorded.  The time of vital sign measurements should be recorded in the source 
documents. Vitals may be repeated, however all measurements taken should be recorded in 
the source documents.  Any repeat readings at a particular timepoint should be recorded as 
unsched uled data points. Subjects should be asked to remain seated for at least 5 minutes 
prior to all measurement s of vital sign parameters.  Vital sign assessments will be performed 
prior to PK sampling when these assessments are collected at the same visit.  
 
Age-appropriate equipment, e.g., blood pressure cuffs, should be used for all assessments.  
 
Physical Examination  – A complete physical examination of the subject will be performed by 
[CONTACT_422230]. Physical examination findings should correlate with the subject’s 
medical history and current diagnosis.  
 
Abbreviated Physical Examination  – An abbreviated physical examination of the subjects 
will be performed by [CONTACT_422230]. This examination reviews only those body 
systems where there has been a change in health or there is new finding to report.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 33 of 77 
  
Laboratory Tests – Urine and blood samples will be collected and sent to a c entral laboratory 
for analysis (see Section 6.3 for details).  Age-appropriate normative clinical laboratory values, 
based on the clinical laboratory’s p aediatric ranges, will be used to determine abnormal 
laboratory values for this study.  
 
Pregnancy Test  – All female subjects of childbearing potential will have a urine  pregnancy 
test performed at all clinic  visits.  Childbearing potential will be defined as any female subject  
who has reported first menses . 
 
Pharmacokinetic Evaluations  – Sample collections fo r the determination of lubiprostone and 
metabolite M3 concentrations will be  performed in all subjects . 
 
Bone Growth Assessments – For those subjects who were aged 6 to 9 or 14 to 17 at the 
time of enrolment into the SAG/0211PFC -1131 study, and who were qu alified to participate 
and enrolled in the DXA substudy , BMD  and BMC  measurement using DXA will be performed 
at Month 9 (Visit 16) . All subjects who withdraw from the study after Visit 12 (Month 3) should 
complete the final visit of the treatment period (Visit 16) and therefore  have a final DXA 
assessment performed.  This will only be required for subjects that were originally part of the 
DXA subgroup . Analysis of scans will be performed by a central reader . 
Any subject demonstrating a decline in 4% in BMD at any skeletal site from Screening to End 
of Treatment should additionally undergo a follow -up DXA  assessment  6 to 12 months later.  
Adverse Events  – AEs will be reported by [CONTACT_456034] -up period. AEs will be followed by [CONTACT_456035]. Further details on AE reporting are provided in Section  7. 
Concomitant Therapy  – An updated concomitant therapy  history of the subject will be 
recorded . The subject must be reminded  that prescription and laxative medications are 
disallowed per Section 5.7.[ADDRESS_582897],  
who has been routinely administering a daily fiber supplement during the preceding double -
blind study (SAG/0211PF C-1131) , may remain on the supplement throughout the study 
provided the regimen and dose does not change.  Similarly, t reatment with anticholinergic 
agents, SSRIs, SNRIs, or MAO inhibitors is allowed if a stable dose has been used for at least 
30 days prior  to the Screening Visit and not likely to change during the study . 
Electronic Diary – The electronic diary dispensed to the subject or parent/legal  guardian  in 
the previous blinded study ( SAG/0211PFC -1131 ) will continue to be used. If necessary the 
subject  or parent/legal guardian  will receive another demonstration and set of instructions for 
use. At enrolment  (Visit 9) , ensure that the electronic diary is set to capture treatment -related 
responses associated with this long-term safety study . The daily diary will record information 
throughout the study . Information from the electronic diary will be automatically transmitted 
from the device each night to a secure study database and will be available for review by [CONTACT_456036].  The parent/legal guar dian and, for certain diary questions, the subject  must  
complete the diary each evening per the instructions . Additionally, the occurrence of bowel 
movements and use of rescue medications can be recorded in real -time throughout the day, 
with the opportunit y to review any epi[INVESTIGATOR_455999]. A maximum 
recall period of 24 hours will be allowed for entry of study -related event data in the diary.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 34 of 77 
  
6.1.2  Enrolment  Period  – Visit 9 (Study Day 1) 
At this visit, a review of the inclusion and exclusion criteria will be conducted for all subjects to 
ensure the subject remains eligible for the study. Consent/assent  must be obtained before any 
study procedures are performed.  
 
Note:  This visit will coinc ide with Visit 7 from the preceding study  (SAG/0211PFC -1131 ). The 
following procedures that are recorded as part of Visit 7 from SAG/0211PFC -1131 will also be 
recorded to this visit and therefore do not need to be repeated:  
 
 Completion of PedsQL™  questionnaire by [CONTACT_456037]/legal guardian  prior to 
conducting other visit procedures ; 
 Measure predose vital signs, including height and weight; measure heart rate and blood 
pressure [ADDRESS_582898] 5 minutes prior to measurement of vital sign parameters. If 
blood pressure and/or heart rate are confirmed to be clinically significantly changed  (as 
defined in Section 6.3) at the [ADDRESS_582899] 
the time of vital sign measurements in the source documents. A wal l-mounted 
stadiometer, where available, should be used for measurement of height . Age-
appropriate equipment, e.g., blood pressure cuffs, should be used for all assessments ; 
 Collect blood and urine samples for clinical laboratory ana lysis. A total of about 5.5 mL 
of blood will be collected for clinical laboratory analysis ; 
 Perform a  full physical examination;  
 Measurement of BMD and BMC  via DXA of lumbar  spi[INVESTIGATOR_456000] (less head), if 
available, for DXA Subgroup (Subjects 6 to 9 and 14 to 17 years of age). This will only 
be required for subjects that were originally part of the DXA subgroup ; and  
 Urine Pregnancy Test – All female subjects of childbearing potential will have a urine 
dipstick pregnancy test to determine their pregnancy status prior to the  dispensing of 
study medication . 
 
As part of this visit, the following procedures will take place:  
 
 Update medical history. Any new medical information should be added to the subject’s 
baseline history  (AEs will be captured on the AE page) ; 
 Collect PK samp les – Pre-dose and 1 sample between 30 and 90 minutes after dose 
administration (2 samples total) . PK samples will be taken under non-fasting conditions. 
The samples will be collected via direct venepuncture. Approximately 8 mL of blood will 
be taken for e ach sample (16 mL in total) such that the total of all PK samples does not 
exceed 50 mL or 5 mL/kg of body weight ; 
 Review and record any new AEs and follow -up on any ongoing AEs;  
 Update Concomitant Therapy – Concomitant medications (prescribed and  over-the-
counter  [OTC ]) used since the last visit  will be reviewed. The subject  or parent/legal 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 35 of 77 
 guardian  should again be instructed not to use any prescription or OTC laxatives unless 
prescribed by [CONTACT_737];  
 Review and discuss rescue medication use and rem ind subject or parent/legal guardian 
to record rescue medication use in electronic diary;  
 The electronic diary dispensed to the subject or parent/legal guardian in the previous 
blinded study (SAG/0211PFC -1131) will continue to be used. If necessary the sub ject or 
parent/legal guardian will receive another demonstration and set of instructions for use. 
Ensure that the electronic diary is set to capture treatment -related responses associated 
with this long -term safety  study ; 
 Dispense first bottle of study med ication, provide dosing instructions and remind the 
subject  or parent /legal guardian  to bring the bottle with any remaining study medication 
to every visit;  
 Observe the subject or parent/legal guardian as he/she administers the first dose of study 
medication while in the clinic. Over the next [ADDRESS_582900] for any adverse 
reactions. Ensure blood pressure and heart rate are collected at 1 hour postdose as 
described above;  
 Schedule the next clinic visit  (Visit 10/Study Day 8 ). 
6.1.[ADDRESS_582901] dose of study 
medication is administered ( Study Day 1) and will end upon administration of the last dose.  
 
Note: If at any time during the study, the subject discontinues from the study , the subject 
should be withdrawn from the study and complete the final visit of the treatment period (Visit 
16) and the Follow -up Visit (Visit 17). All subjects who withdraw from the study after Visit 12 
(Month 3) should have a final DXA assessme nt performed.  The DXA assessment  will only be 
required for subjects that were originally part of the DXA subgroup . 
 
[IP_ADDRESS]  Interim Clinic Assessment  – Visit 10 (Week  1/Day 8 ± 2 days ) 
During th is visit, the following procedures will be performed:  
 
 Measure vital signs, including height and weight . Subjects should be asked to remain 
seated for at least [ADDRESS_582902] the 
time of vital sign measurements in the source documents. A wall -mounted stadiometer, 
where availa ble, should be used for measurement of height . Age-appropriate equipment, 
e.g., blood pressure cuffs, should be used for all assessments ; 
 Perform an abbreviated physical examination;  
 Collect blood and urine samples for laboratory analysis (including a preg nancy test, if 
applicable) . A total of about 5.5 mL of blood will be collected for clinical laboratory 
analysis ; 
 Review and update concomitant therapy;  
 Review and record any new AEs and follow -up on any ongoing AEs;  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 36 of 77 
  Review and discuss rescue medication use  and remind subject or parent/legal guardian 
to record rescue medication use in electronic diary;  
 Review compliance associated with completion of the electronic diary ; 
 Collect the previously dispensed bottle of study medication and perform drug 
accountability. Review study medication compliance with the subject  and/or parent/legal 
guardian .  If the study medication is not returned, the bottle of all unused study medication 
should be returned to the site  at the subsequent office visit ; 
 Dispense new supply of study medication  (3 bottles ). The subject  and/or legal guardian  
will be instructed to take the study medication only from the newly dispensed bottle s; 
 Confirm the next telephone contact  (i.e., at Study Day 29 ). 
 
[IP_ADDRESS]  Interim Telephone Assessments – Visits 11, 13 and 15 (Week  4/Day 29 ±3 days , 
Week 16/Day 113 ±3 days,  and Week 28/Day 197 ±3 days )  
During these telephone assessments , the following procedures will be performed:  
 
 Review and update concomitant therapy;  
 Review and record any new AEs and follow -up on any ongoing AEs;  
 Review compliance associated with study medication;  
 Review and discuss rescue medication use and remind subject or parent/legal guardian 
to record rescue medication use in electronic diary;  
 Review compliance associated with co mpletion of the electronic diary ; 
 Confirm the next scheduled clinic visit.  
[IP_ADDRESS]  Interim Clinic Assessment  – Visits 12 and 14 (Week  12/Day 85 ±3  days and Week 
24/Day 169 ±3 days ) 
During  these visits, the following procedures will be performed:  
 
 Completion of PedsQL™  questionnaire by [CONTACT_456037]/legal guardian  prior to 
conducting other visit procedures ; 
 Measure vital signs, including height and weight . Subjects should be asked to remain 
seated for at least [ADDRESS_582903] the 
time of vital sign measurements in the source documents. A wall -mounted stadiometer, 
where available, should be used for measurement of height . Age-appropriate equipment, 
e.g., blood pressure cuffs, should be used for all assessments ; 
 Perform an abbreviated physical examination;  
 Collect blood and urine samples for clinical laboratory analysis (including a urine 
pregnancy test if applicable ). A total of about 5.5 mL of blood will be collected for clinical 
laboratory analysis ; 
 Review and up date concomitant therapy;  
 Review and discuss rescue medication use and remind subject or parent/legal guardian 
to record rescue medication use in electronic diary;  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 37 of 77 
  Review and record any new AEs and follow -up on any ongoing AEs;  
 Review compliance associated with completion of the electronic diary;  
 Collect the previously dispensed bottle of study medication and perform drug 
accountability. Review study medication compliance with the subject  or parent/legal 
guardian .  If the study medication is not r eturned, the bottle of all unused study medication 
should be returned to the site at the subsequent office visit;  
 Dispense new supply of study medication  (3 bottles ). The subject will be instructed to 
take the study medication from the newly dispensed bott les; 
 Sche dule the next telephone contact . 
[IP_ADDRESS]  End-of-Treatment Visit – Visit 16 (Week 36/Day 253 +3 days )  
During  this visit, the following procedures will be performed:  
 
 Completion of PedsQL™  questionnaire by [CONTACT_31384]/legal guardian prior to 
conducting other visit procedures ; 
 Measure vital signs, including height and weight . Subjects should be asked to remain 
seated for at least [ADDRESS_582904] the 
time of vital sign measurements in the source do cuments. A wall -mounted stadiometer, 
where available, should be used for measurement of height . Age-appropriate equipment, 
e.g., blood pressure cuffs, should be used for all assessments ; 
 Perform a full physical examination;  
 Collect blood and urine samples for clinical laboratory analysis (including a urine 
pregnancy test if applicable ). A total of about 5.5 mL of blood will be collected for clinical 
laboratory analysis ; 
 Measurement of BMD and BMC  via DXA of lumbar  spi[INVESTIGATOR_456000] (less head), if 
available  for those s ubjects enrolled in DXA subgroup only ; 
 Review and update concomitant therapy;  
 Review and record any new AEs and follow -up on any ongoing AEs;  
 Review compliance  associated  with completion of the electronic diary;  
 Collect the previously dispensed bottle of study medication and perform drug 
accountability. Review study medication compliance with the subject  and/or parent/legal 
guardian .  If the study medication is not returned, the bottle of all unused study 
medication must be returned to the site  at the subsequent office visit.  
6.1.4  Follow -up Period   
The follow -up period lasts for 4 weeks following the final dose of study medication. AEs should 
be followed to assess their status and resolution during this timeframe. Any new concomitant 
medicati ons should also be recorded.   
[IP_ADDRESS]  Follow -up (Clinical  Assessment ) – Visit 17 (Week 40/Day 281 +3 days )  
The follow -up visit is scheduled to assess all AEs since  the end of  treatment to determine if 
resolution has occurred or update the ongoing status of these events. Also , any new events 
should be recorded. A review of the subject’s concomitant therapy should be made to 
determine if any changes have been made.   
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 38 of 77 
 At this visit, the following procedures will be performed:  
 Review and update concomitant therapy;  
 Review and record any new AEs a nd follow -up on any ongoing AEs;  
 Vital signs including height and weight ; 
 Abbreviated physical examination ;  
 Collect blood and urine samples for clinical laboratory analysis  (including a urine 
pregnancy test if applicable ). A total of about 5.5 mL of blood will be collected for 
clinical laboratory analysis ; and  
 Collect electronic diary . 
 
6.1.5  Unscheduled Visit(s)  
Additional visits  may be sch eduled, at the discretion of the Investigator, to ensure the safety 
and well -being of subjects who experience AEs during the course of the study warranting 
further evaluation. Any additional visits  should be fully documented in the subject’s eCRF on 
the Un scheduled Visit Screen(s).  
 
6.2 Efficacy Evaluations  
The parent/legal guardian and, in some cases, the subject him/herself  will answer questions 
about the  subject’s  constipation, including recordation of bowel movements (BMs), associated 
stool consistency and bowel straining  ratings , as well as evaluations  of abdominal pain, 
constipation severity, and treatment effectiveness . This information will be assessed as part of 
the daily and weekly evaluations recorded in the electronic diary. Additionally, subjects wi ll 
complete the PedsQL™  questionnaire at all clinic visits (except Visit s 10 and 17 ), with 
responses recorded on paper  at specified clinic visits.  
 
6.2.1  Electronic Diary  
The electronic diary is a hand -held device with a visual display. It is designed to query the 
parent/legal guardian daily  about the status of their child’s constipation  (see Appendix 1 ). The 
diary will prompt the parent/legal guardian and, in some cases, t he subject to provide 
information each evening prior to bedtime about the constipation -related events during the 
preceding day  or week . Additionally, the occurrence of bowel movements and use of rescue 
medications can be recorded in real -time throughout th e day, with the opportunity to review 
any epi[INVESTIGATOR_455999]. A maximum recall period of [ADDRESS_582905] diary is automatically trans mitted each night to a secure study 
database and available for review by [CONTACT_456038]. Since the diary information is being 
gathered for efficacy, it is important that the diary is completed  each day.  Additional information 
about the electronic diary  and its usage will be provided to the sites in a reference manual 
prepared by [CONTACT_456039].   
 
6.2.2  Efficacy Endpoint s 
The efficacy endpoint s are provided in Section 2.2.1 .  
 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 39 of 77 
 6.3 Safety Evaluations  
The following safety evaluations will be performed during the study to measure the safety of 
the study medication:  
 
Adverse Events: AEs will be reported by [CONTACT_423] f rom the time of informed consent  
through the end of the follow -up period. AEs will be followed by [CONTACT_456035]. Further details on AE reporting are provided in Section  7. Any study 
medication related AEs persisting at the end of the study will be followed until resolution, or 
until a clinically stable endpoint has been reached.  
 
In this study, f aecal impaction and bone fractur es will be captured as AE s. The events of faecal 
impaction will be used for the analysis of the fecal impaction frequency during the study (see 
Section [IP_ADDRESS] ). 
 
Clinical Laboratory Tests: The following laboratory tests will be conducted and the 
appropriate Investigator shall determine the clinical significance of any out -of-range values.  
 
 Hematolo gy Panel:  Hemoglobin, hematocrit, MCV, MCH, MCHC, RBC, WBC, white 
blood cell with absolute counts and percent differentials (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils), platelet count.  
 
 Chemistry Panel:  Total cholesterol, triglycerides, glucose, total protein, albumin, 
alkaline phosphatase, AST, ALT, GGT, iron, LDH, total bilirubin, direct bilirubin, BUN, 
uric acid, creatinine, sodium, potassium, chloride, bicarbonate, calcium, phosphorus, 
magnesium.  
 
 Urinalysis:  Protein, glucose, ketones, occult blood, pH, specific gravity, color, 
appearance, leukocyte esterase, nitrite, bilirubin, and m acroscopic examination.   
Microscopic examination will be done if abnormalities are present.  Urine samples will be 
collected, when possible.  
 
Physical Examination: Physical examinations will be conducted at various timepoints during 
the study. Any new post treatment findings or changes, as noted by [CONTACT_737], will be 
reported as an AE.  
 
Vital Signs:  
Vital signs (in cluding height and weight  at designated visits ) will be recorded during the study. 
Any post treatment clinical ly significant changes in vital signs (including weight) shall be noted 
by [CONTACT_456040].  Additional guidance regarding a ssessment of 
changes in blood pressure and heart rate are provided below.  
 
Normal blood pressure ranges will be based on the National Institutes of Health National Heart, 
Lung, and Blood Institute chart ( Appendix 2 ). If, at [ADDRESS_582906] be reported as an adverse 
event.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 40 of 77 
  
Normal heart rate ranges will be based on the Silverman pediatric ranges ( Appendix 3 ). If, at 
1 hour postdose, a change in heart rate of greater than 20 beats per minute ( bpm) from the 
predose assessment is observed, and this change is confirmed by a repeat measurement, 
additional measurements must be taken at [ADDRESS_582907] be reported as an adverse event.  
 
Rescue Medication Usage: All medications used emergently by [CONTACT_456041], will be captured during their participation in the study.  
 
Bone Growth Assessments: BMD  and BMC  assessments will be performed during the study  
for those subjects enrolled  in DXA Subgroup  only.  
 
Any subject demonstrating a decline in 4% in BMD at any skeletal site from Screening to End 
of Treatment should additionally undergo a follow -up DXA assessment 6 to 12 months later.   
 
6.3.1  Pharmacokinetic Evaluation   
Plasma samples will be collected from all subjects and  analy sed to determine levels of 
lubiprostone (if measurable) and metabolite M3 . These concentration -time data will be used in 
a population PK analysis. PK samples will be taken under non-fasting conditions. The  samples 
will be co llected via direct venepuncture . Approximately 8 mL of blood will be taken for each 
sample such that the total of all PK samples does not exceed 50 mL or 5 mL/kg of body weight.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582908] a causal relationship with this treatment. An AE can therefore be any unfavorable and 
unintended sign (includi ng an abnormal laboratory finding), symptom, disease or exacerbation 
of a pre -existing condition temporally associated with the use of a medicinal (investigation) 
product, whether or not related to the medicinal product.  For this study, all safety informat ion 
will be collected from the time of informed consent and any untoward medical occurrence after 
enrolment  will be defined as an AE. Adverse events that are reported after initiation of study 
medication will be defined as treatment -emergent AEs.  
 
In this study, faecal impaction and bone fractures will be captured as AE s. The events of faecal 
impaction will be used for the analysis of the f aecal impaction frequency during the study (see 
Section [IP_ADDRESS] ). 
 
Each AE requires a complete and thorough description including date of onset, duration, 
intensity/severity, its relationship to the study drug and any corrective actions taken. Each AE 
should also be categorized as “ serious” or “non -serious”.  
 
Timely, accurate, and complete reporting and analysis of safety information from the clinical 
study are crucial for the protection of subjects and are mandated by [CONTACT_223912].  
 
7.1 Definitions and Descriptions  
7.1.1  Serious Adverse Event  
A serious adverse event (SAE) is any untoward medical occurrence that, at any dose:  
 Results in death;  
 Is life -threatening (the subject was at risk of death at the time of the event. It does not 
refer to an event which hypothetically m ight have caused death if it were more severe);  
 Requires hospi[INVESTIGATOR_1081];  
o This criterion applies if the event requires inpatient hospi[INVESTIGATOR_456001], if in the opi[INVESTIGATOR_871], prolongs an existing 
hospi[INVESTIGATOR_059].   
o Hospi[INVESTIGATOR_456002] 24 hours with no admission are not considered 
“hospi[INVESTIGATOR_059]”.  
o A hospi[INVESTIGATOR_059] (including hospi[INVESTIGATOR_456003] -planned procedures) for a pre -existing condition which 
has not worsened does not constitute an SAE.  
 Results in persistent or significant disability/incapacity;  
 Is a congenital anomaly/birth defect; and/or  
 Is an important medical event (an event that may not fit the other criteria for a SAE as 
listed above, but based upon appropriate medical judgment, may jeopardize the subject 
or may require intervention to prevent one of the outcomes listed above). Examples of 
such events  (per 21 CFR 312. 3215) are intensive treatment in an emergency room or at 
home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospi[INVESTIGATOR_456004].  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 42 of 77 
 7.1.2  Non-serious Adverse Event  
A non -serious AE is any  event that does not meet the above -mentioned SAE definition.  
7.1.3  Severity  
The severity of each AE will be determined based upon the follow ing criteria:  
 
Mild: Transient symptoms, no interference with subject’s daily activities.  Less 
than 48 hours, no medical intervention/therapy required.  
Moderate : Marked symptoms, moderate interference with the subject’s daily 
activities.  No or minimal medical intervention/therapy required.  
Severe :  Considerable interference with the subject’s daily activities.  Medical 
intervention/therapy required; hospi[INVESTIGATOR_9841] . 
7.1.4  Relationship to Study Medication  
The relationship to study medication will be determined and recorded on eCRF by [CONTACT_456042] (WHO) 
classification : 
 
Causality  Definition  
Unrelated  
 Concurrent illness, concurrent medication, or other known cause is clearly responsible 
for the adverse event OR based upon available information regarding subject history, 
disease process, relationshi p of adverse event to dosing, and drug pharmacology, a 
relationship between the drug and adverse event is unlikely.  
Possible  The adverse event follows a reasonable sequence from the time of drug administration, 
but could also have been produced by [CONTACT_423] ’s clinical state or by [CONTACT_456043] .  
Event with a time to drug intake that makes a relationship improbable (but not 
impossible). Disease or other drugs provide plausible explanations  
Probably  The adverse event follows a  reasonable sequence from the time of drug administration, 
follows a known response pattern of the study treatment class, is confirmed by 
[CONTACT_3895][INVESTIGATOR_456005].  
Event with reasonable time relationship to drug intake : 
• Unlikely to be attributed to disease or other drugs  
• Response to withdrawal clinically reasonable  
• Rechallenge not required  
Definite  The adverse event follows a reasonable sequence from the time of drug administration, 
follows a known response pattern of the study treatment class, is confirmed by 
[CONTACT_3895][INVESTIGATOR_217909], and there is no other reasonable cause 
exists.  
 
7.1.5  Onset and Duration  
The date and time the event was reported to investigator  will be recorded, as well as the start 
date and time  and resolution date and time of  the event.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 43 of 77 
 7.2 Recording and Reporting of Adverse Events  
All AEs will be recorded in the source document and applicable eCRF(s) from the time the 
informed consent is signed until the end of study. AEs occurring prior to the first dose of study 
drug will be considered non -treatment emergent.  Any ongoing AEs will be followed until they 
are resolved, stabilized, or until 30 days after the end of treat ment exposure . The Investigator 
shall notify the Sponsor at any time when an SAE is believed to be related to the administration 
of study medication, even after the end  of the study.  At any time during the study, those events 
meeting the definition of an Immediately Reportable Event (IRE)  must be recorded on  source 
document, IRE Reporting Form, and applicable eCRF(s), and then reported to Sponsor or 
designee using the IR E Reporting Form as specified in Section 7.2.[ADDRESS_582909]’s participation in the study, must be followed until either:  
 the event resolves;  
 the event stabilizes;  
 the event returns to baseline, if a baseline value is available;  
 the event can be attributed to other than the study medication, or to other than study 
conduct ; 
 the Investigator does not anticipate an y further improvement or worsening of the event.  
All AEs, regardless of seriousness, severity or presumed relationship to study medication, 
must be recorded using medical terminology in the source docum ent and in the eCRF. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a 
common etiology (e.g., cough, runny nose, sneezing, sore throat, and head congestion should 
be reported as “upper respi[INVESTIGATOR_4416]”). Investigators must record on the source 
document and eCRF their opi[INVESTIGATOR_456006]. All measures required for AE management must be recorded in the 
source document and reported according to Sponso r instructions.  
7.2.1  Reporting of Immediately Reportable Events  
The following events, regardless of severity or seriousness, are considered immediately 
reportable IREs and are to be reported via the IRE Form within 24 hours to the Sponsor or 
designee:  
 All Serio us Adverse events ; 
 All pregnancies ; and  
 Events of Special Interest (list all events of special interest) . 
o Chest pain/chest discomfort  
o Dyspnea/shortness of breath/difficulty breathing  
o Hepatotoxicity/liver enzyme increased  
o Anaphylaxis, including anaphylactoid reaction and anaphylactic shock  
 
Immediately Reportable Events, such as SAEs, should be recorded on the Adverse Event 
source document and eCRF. In addition, any IRE occurring during the clinical study must be 
reported within [ADDRESS_582910] provide the following information: protocol number, 
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582911]’s initial s and study number  AE term and associated dates, causal relationship between 
the event and study medication, relevant history, study medication dosing details, full 
description of the event, and other required data within the IRE form. All oral reports of an IRE 
must be followed immediately by a facsimile of the IRE form signed by [CONTACT_737]. 
Investigators should not leave oral reports of IREs on any voicemail aside from the Sponsor’s 
Medical Monitor or designee.  The details of the adverse event repor ting requirement are also 
outlined in a safety reporting plan.  
 
The Sponsor assumes responsibility for reporting of expedited and periodic safety reports to 
the appropriate regulatory authorities. The Sponsor will report to the Investigator any new 
safety events occurring in other studies. The Investigator may need to report SAEs to the 
appropriate IRB/IEC in accordance with local regulations.  
[IP_ADDRESS]  Reporting of Pregnanc ies 
Any pregnancy occurring in a female subject after the first intake of study medication, wh ile 
not an AE, is considered an IRE. It must be reported within [ADDRESS_582912], who becomes pregnant, shall 
be removed from the clinical study and followed for the duration  of the pregnancy. Follow -up 
information regarding the outcome of the pregnancy and any postnatal sequelae in the infant 
up to one year of age will be required.  
 
7.2.2  Outcome  
The investigator should follow all IREs until resolution (return to baseline status) or loss to 
follow -up or until no further improvement or worsening of the participant’s condition is 
expected. Loss to follow -up implies that the Investigator site is no longer aware of the 
participant’s whereabouts, and is unable to obtain current contact [CONTACT_3031]. All attempts to 
contact [CONTACT_456044].  
7.2.[ADDRESS_582913] be taken into consideration.  
If, at the end of the treatment phase, there are pathological laboratory values which were not 
present at baseline, per investigator discretion further clinical or laboratory investigations 
should be p erformed until the values return to within reference range or until a plausible 
explanation (e.g., concomitant disease) is found for the pathological laboratory values.  
Sucampo AG  CONFIDENTIAL   
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582914], whether a change in a laboratory parameter is clinically significant and therefore 
represents an AE.  
7.2.5  Vital Signs  
A change in the value of a vital sign measurement can represent an AE, as discussed in 
Section 6.3 for blood pressure and heart rate. The Investigator should decide, based on the 
criteria in Section 6.3, or per their discretion (for other vital sign measur ements), and the clinical 
condition of a subject, whether a change in vital signs is clinically significant and therefore 
represents an AE.  
7.2.6  Overdose  
There are no specific treatments or monitoring guidelines prescribed for subjects  with 
lubiprostone overdose. It will be left to the discretion of the Investigator ’s clinical judgment on 
how to provide appropriate symptomatic treatment.   
 
Any incidences of overdose with the investigational product will follow the same reporting 
proced ures as an AE (see Section 7.2 ), and only where applicable, as an IRE (see Section 
7.2.1 ).  
7.[ADDRESS_582915] of the trial needs to be addressed by 
[CONTACT_1689]. The names of the individuals (and corresponding telephone numbers) 
who should be contact[CONTACT_456045].  
7.4 Coding of Adverse Events  
All AEs will be coded by [CONTACT_1034]’s designee using the current Medical Dictionary for 
Regu latory Activities (MedDRA)® terminology.  
 
7.[ADDRESS_582916] (DSMB) will monitor safety data on a regular basis throughout 
the study. Specific details, including meeting frequency  and stoppage criteria, are provided in  
the DSMB Charter.  
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582917] of the preceding double -
blinded study (SAG/0211PFC -1131), bottles will not specifically identify whether they contain 
lubiprostone [ADDRESS_582918] 50 kg in weight at the time of randomisation in the 
preceding study (SAG/0211PFC -1131). All dose assignment s will be handled by [CONTACT_456046]. Investigators will be provided with subject treatment dose information associated with their 
study participants upon finalisation of the Clinical Study Report.  
8.1 Determination of Sample Size  
The sample size goal is based on the expected attrition that would occur and the remaining 
number of safety evaluable subjects at each timeframe during the study.   
8.2 Datasets Analy sed 
Two analysis populations, Safety population and the modified Intent -to-Treat ( mITT) population  
and the se will be defined as follows:  
 The Safety population  will consist of a ll enrolled  subjects who take at least one dose 
of study medication . 
 The mITT population  will include all enrolled  subjects who take at least one  dose of 
study medication and have at least one treatment period diary entry .  
8.[ADDRESS_582919]’s evaluation of BM frequency rates, SBM frequency rates, stool consistency, 
bowel straining, abdominal pain, constipation s everity, incontinence epi[INVESTIGATOR_1841], occurrence of 
large diameter stools, retentive posturing, and the health -related qu ality of life using the 
PedsQL™  questionnaires. These data will be summarized with descriptive statistics as 
outlined above . 
8.4 Analysis of Expo sure to Study Medication, Rescue Medication, and 
Concomitant Medication  
Assessments of actual exposure to study medication and rescue medication will be made 
based on the eCRF and diary data. Results will be summarized by [CONTACT_9086].  
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 47 of 77 
 Concomitan t medications will be classified by [CONTACT_38375] (WHO) medical 
dictionary, and numbers and percentages of subjects receiving each classified medication will 
be calculated for all medications.  
8.5 Analysis of Safety  
8.5.1  Deaths, Serious Adverse Even ts, and Adverse Terminations  
Subjects with these critical events will be identified in separate listings, with the event, timing 
and outcome information and relevant demographic and baseline data.  
8.5.2  Adverse Events  
The original terms used in the eCRF by [CONTACT_456047]® 
system organ class and preferred terms. Adverse events  will be summarized in terms of 
incidence per dose group and overall. The incidence of an AE is defined as the number of 
subjects who experienced at lea st one epi[INVESTIGATOR_1863].  Adverse event incidence rates 
will be summarized by [CONTACT_9313] (SOC) and preferred term (as determined by [CONTACT_456048]).  
Whatever the level of classification, if a subject experiences multiple epi[INVESTIGATOR_456007], then the event is only counted once. Further, for summaries 
by [CONTACT_456049], the most severe event is chosen for a subject if that subject 
experiences multiple epi[INVESTIGATOR_246501].  
In this study, faecal impacti on and bone fractures will be captured as AEs. The events of faecal 
impaction will be used for the analysis of the f aecal impaction frequency during the study (see 
Section [IP_ADDRESS] ). 
AEs with onset dates after administration of the first dose of study medication or prior to  the 
last day of treatment + 7 days will be considered treatment -emergent. Events with completely 
or partially missing onset dates will be included in the tabulations, unless the available partial 
date information clearly indicates that the event happened outside of the treatment period.  
P-values from Fisher’s exact test or chi -square test will be presented in the AE summary tables. 
The test will be performed to compare incidence rates at the SOC and “At Least One Event” 
level between the two treatment groups.  
8.5.[ADDRESS_582920] -treatment visits will be 
summarized usi ng descriptive statistics. Cross -tabulations analysis will be performed for 
laboratory parameters with reference normal ranges. The laboratory data will be categorized 
as low, within, and above the reference normal ranges. The summary tables will tabulate the 
number and percentage of subjects with pre -treatment values below/within/above the normal 
reference range versus minimum/maximum/final post -treatment values below/within/above the 
normal reference range. Normal reference ranges will also be provided in  the summary display. 
Laboratory parameters that are not specified in the protocol will not be included in the analysis, 
but they will be provided in the individual subject listings.  
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 48 of 77 
 8.5.4  Physical Examinations  
Subjects with changes from normal at baseline to a bnormal during the treatment period in any 
organ system will be identified and listed.  Shift tables, which indicate incidence rates of 
changes from (normal, abnormal) at baseline to (normal, abnormal) values at each visit , will 
be presented.  
8.5.5  Bone Growth As sessments  
Bone growth will be assessed on the DXA s ubgroup population (i.e., those s ubjects who were 
aged 6 to 9 or 14 to 17 at the time of enrolment into the SAG/0211PFC -1131 study, and who 
were qualified to participate and enrolled in the DXA substudy ). Bone -related DXA endpoints 
will include:  
 Percent changes from baseline in BMD and BMC;  
 Change from baseline in BMD Z -scores and in height -adjusted Z -scores;  
 Changes  from baseline  in height and weight Z -scores.  
Details on analyses by a ge, race,  and gende r subgroups are provided in the SAP . 
8.5.[ADDRESS_582921] s, or healthy volunteers. A separate analysis plan 
for the population pharmacokinetic analysis will be prepared prior to database lock.  
8.5.8  Subgroup and Exploratory Analyses  
Upon completion of pi[INVESTIGATOR_30338] 3 studies, analyses of any under -represented subgroups 
such as males and  non-whites  will be performed on the pooled data from the pi[INVESTIGATOR_36491]. 
Details pertaining to these analyses will be specified in the SAP . 
8.6 Analysis of Efficacy  
8.6.1  General Inferential Principles  
The following principles apply for all inferential analyses of efficacy: All tests are two -tailed at 
a significance level of α = 0.05.   
[IP_ADDRESS]  Missing Data  
Details on handling of missing data  are described in the SAP . 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 49 of 77 
 [IP_ADDRESS]  Multiplicity  
No interim analyses will be performed and therefore no multiplicity adjustments will need to be 
made to a ccount for them.  
[IP_ADDRESS]  Multi centre  Studies  
Region and/or centre effects will be explored as detailed in the SAP . 
8.6.2  Efficacy  Endpoints  
[IP_ADDRESS]  Overall and Monthly Change from Baseline in BM and SBM Frequency  
Change s from baseline in BM and SBM frequency will be analy sed overall, and at each month 
from Months 1  through Month 9 . A month is defined as a 4 -week period; e.g., Month 1 is Weeks 
1-4; Month 2 is Weeks 5 -8; Month 3 is Weeks 9 -12. The SBM frequency rate per week will be 
computed as specified in Section [IP_ADDRESS] . The analyses of the months will utilize the same 
methods as those used in the analysis of weeks.  
[IP_ADDRESS]  Overall and Monthly Change from Baseline in Incontinence Frequency  
This analysis will be performed for subjects who are fully toilet -trained  and for the subset of 
subjects presentin g with incontinence at baseline . Change from baseline in incontinence  
frequency will be analy sed overall, and  at each month during Months  1 through 9  as described 
in Section [IP_ADDRESS] . 
[IP_ADDRESS]  Overall and Monthly Change from Baseline in Production of Large Diameter Stool 
Frequency  
This analysis will be performed  for subjects who are fully toilet -trained. Change from baseline 
in the production of large diameter stool  frequency  will be analy sed overall, and  at Months 1  
through 9 as described in Section [IP_ADDRESS] . 
[IP_ADDRESS]  Overall and Monthly Change from Baseline in Proportion of BMs  and SBMs  in Toilet  
This analysis will be performed for subjects who are fully toilet -trained. Change from baseline 
in the proportion of BMs  and SBMs  in the toilet  will be analy sed overall, and  at each month 
during  Months 1  through 9 as described in Section [IP_ADDRESS] . 
[IP_ADDRESS]  Overall and Monthly Change from Baseline in Frequency of F aecal Impaction  
Change from baseline in faecal impaction  frequency will be analy sed overall, and  at each 
month during Months  1 through 9 as described in Section [IP_ADDRESS] . 
[IP_ADDRESS]  Overall and Monthly Change from Baseline in Frequency of Retentive Posturing or 
Excessive Volitional Stool Retention  
Change from baseline in retentive posturing or excessive volitional stool retention  frequency 
will be analysed  overall, and  at each treatment month  during Months 1 through 9  as described 
in Section [IP_ADDRESS] . 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 50 of 77 
 [IP_ADDRESS]  Overall and Monthly Change from Baseline in Constipation Signs and  Symptoms  
Mean change s from baseline will be generated based on subject reported data as to the degree 
of: 
 Straining associated with SBMs;  
 Stool consistency of SBMs;  
 Abdominal pain associated with SBMs ; and 
 Constipation severity . 
The following rating scales will be  used:  
Stool consistency: Modified Bristol Stool Form Scale (5 -point scale);  
Bowel straining: 0=Not at all, 1=A little, 2=Some, 3=Quite a bit, 4=Extremely  
Constipation severity  and abdominal pain: 0=Absent, 1=Mild, 2=Mo derate, 3=Severe, 4=Very 
severe.  
The overall change from baseline will be calculated as the baseline value subtracted from the 
average of all diary ratings, where the baseline value will represent the average rating during 
the 2 -week screening period  of the previous study (SAG/0211PFC -1131) . The change from 
baseline for a week ( 7-day period ) or month (4 -week period) will also be calculated as the 
baseline value subtracted from the average of all diary ratings during a week or month.  
Stool Consistency  
The anal ysis of stool consistency will focus on consistency assessments associated with 
SBMs. The average stool consistency rating will be calculated for each month (4 -week period), 
excluding measurements recorded within 24 hours after rescue medication intake.  
Analyses will be based on the change from baseline, where the baseline value will represent 
the average stool consistency rating from all SBMs during the 2 - week screening period  of the 
previous study ( SAG/0211PFC -1131 ). The van Elteren test using the change  from baseline 
stratified by [CONTACT_456050].  
Straining  
Bowel straining will be analy sed in a metho d similar to stool consistency.  
Constipation Severity  
The changes from baseline in mean constipation se verity ratings at each month during Months 
[ADDRESS_582922] dose of study medication (Day 1). For example , Month 1 will start with the daily 
assessment on Day 1 and end with the daily assessment on Day 2 9 (Week 4), Month 2 will 
start with the  daily assessment on Day 30 and end with the daily assessment on Day 5 7 (Week 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 51 of 77 
 8), and Month 3 will start with the daily assessment on Day 5 8 and end with the daily 
assessment on Day 8 5 (Week 12). Each week will be defined by 7-day intervals beginning with 
the day of the first dose of study medication (Day 1).  
The van Elteren test using the change from baseline stratified by [CONTACT_456051].  
Abdomina l Pain  
Abdominal pain will be analy sed similarly to constipation severity. Summary tables for the 
monthly change from baseline will also be presented.  
[IP_ADDRESS]  Monthly SBM Response  
A monthly responder is defined as a subject who is a weekly responder for [ADDRESS_582923] who has a frequency rate of ≥ 3 SBMs/week 
and an increase from baseline of ≥ 1 SBM/week for that week. Analyses of the frequency rates 
of SBMs per month will be performed using the van Elteren test, stratified by [CONTACT_456052] . 
[IP_ADDRESS]  Treatment Effectiveness  
Measurements of treatment effectiveness will be collected via the diary at weekly intervals as 
well as overall using the following scale: 0 = Not at all effective, 1 = A little bit effective, 2 = 
Moderately effective, 3 = Quite a bit effective, 4 = Extremely effective.  
[IP_ADDRESS]  Health -related Quality of Life  
Health -related quality of life will be measured using the PedsQL™  questionnaire.  
The PedsQL™ questionnaire  has 4 subscales: physical functioning, emot ional functioning, 
social functioning, and school functioning; in addition, there is a total score. Summary 
evaluations of response for every domain and total score at each timepoint will be provided by 
[CONTACT_2939]. For each subscale and for the total sc ore, the change from baseline at each 
visit will be analy sed. 
8.7 Data Quality Assurance  
Steps to be taken to assure the accuracy and reliability of data include the selection of qualified 
Investigator s and appropriate study sites, review of protocol procedure s with the Investigator 
and associated personnel prior to the study, and periodic monitoring visits by [CONTACT_95346]. Compliance will be achieved through a combination of study specific audits of 
investigational sites and audits at regular interv als of the Sponsor’s systems for data handling, 
analysis, and reporting. eCRFs will be reviewed for accuracy and completeness by [CONTACT_456053] -site monitoring visits and any discrepancies will be resolved 
with the Investigator  or design ees, as appropriate. The data will be entered into the clinical 
study database and verified for accuracy.  
This study will be organised, performed, and reported in compliance with the Sponsor’s 
Standard Operating Procedures, protocols and working practice d ocuments, and the 
requirements of national and international GCP guidelines.  
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 52 of 77 
 8.8 Data Collection  
Original source data will be collected via source documents.  Final data for this study will be 
collected using electronic case report forms (eCRFs). Data must be  entered onto the eCRFs 
in English. All eCRFs must be completed in a timely manner before the Sponsor or designee 
performs a monitoring visit. The Principal Investigator [INVESTIGATOR_456008]. Laborator y reports must be reviewed, signed, and dated by 
[CONTACT_456054]. Any laboratory findings out 
of the normal range should indicate the clinical significance (clinically significant [CS] or not -
clinically signi ficant [NCS]) of the results on both the source document and the corresponding 
eCRF.  
The eCRFs are to be completed as soon as possible from the time of the subject’s visit, with 
the exception of results of tests performed outside the Investigator’s office,  so that they always 
reflect the latest observations on the subjects participating in the study.  
All eCRF corrections are to be made or reviewed by [CONTACT_456055].  
Automatically generated queries will be answered  by [CONTACT_456056].  
The dates of the monitoring visits will be recorded by [CONTACT_413774] a study site visit log to be 
kept at the site. The first post initiation visit will usually be made  as soon as possible after 
enrolment has begun. At these visits, the monitor will compare the data entered into the eCRFs 
with the hospi[INVESTIGATOR_40961] (source documents). Source documentation must be 
available to substantiate proper informed consent procedures, adherence to proto col 
procedures, adequate reporting and follow -up of AEs, administration of concomitant 
medication, medication receipt/dispensing/return records, and study medication administration 
information. Specific items required as source documents will be reviewed w ith the Investigator 
prior to the study. Findings from this review of eCRFs and source documents will be discussed 
with the Investigator. The Sponsor expects that, during monitoring visits, the Investigator and 
study coordinator, will be available, the original source documentation , regardless of media,  
will be available, and a suitable environment will be provided for review of study -related 
documents.  
 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 53 of 77 
 9. SPONSOR’S AND INVEST IGATOR’S R ESPONSIBILITIES  
This study will be conducted in accordance with current applicable regulations, International 
Conference on Harmonisation  (ICH), European Union ( EU) Directive 2001/20/ EC17 and local 
ethical and legal requirements.  
9.1 Sponsor’s Responsibilities  
9.1.[ADDRESS_582924] been delegated will undertake their roles for this study in compliance with all applicable 
regulations, ICH GCP Guideline E614and EU Directive 2001/2 0/EC.[ADDRESS_582925] study 
data, subjects’ medical records and CRFs in accordance with current GCP and the respective 
local and national government regulations and guidelines. Records and data may additionally 
be reviewed by [CONTACT_6663], interested commercial parties or by [CONTACT_12721].  
9.1.2  Regulatory Approval  
The Sponsor  will ensure that Local Regulatory Authority requirements are met before the start 
of the study.  The Sponsor  (or a nominated designee) will be responsible for the preparation, 
submission and conf irmation of receipt of any Regulatory Authority approvals required prior to 
release of investigational product for shipment to the study site.  
9.1.3  Indemnity/liability and Insurance  
Sponsor  will adhere to the recommendations of the Association of British Pharma ceutical 
Industry (ABPI) Guidelines.  If appropriate, a copy of the Indemnity document will be supplied 
to the Investigator before study initiation.  
Sponsor  will ensure that suitable insurance cover is in place p rior to the start of the study.  
9.1.[ADDRESS_582926] to investigational sites within the EU, the Sponsor  will submit an end of trial 
notification to individual Member States and IECs within 90 days of the end of the trial in 
accordance with EU Directive 2001/20/EC .17 
The end of trial notification should be made when:  
 the trial ends in the territory of the member state(s) concerned ; and  
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 54 of 77 
  the complete trial has ended in all participating centres in all countries within and outside 
the EU.  
For the purposes of this notification, the end of the complete trial will be defined as the last 
subject/last visit in all participating centres in all countries within and outside the EU and the 
end of trial in a member state will be defined as the last subject last visit in that  member state.  
However, if recruitment into the trial as a whole is on -going and there is a possibility that further 
subjects may be recruited into the trial in a member state where there are currently no active 
subjects, the end of trial notification for that member state will be deferred until it is certain that 
no further subjects will be recruited into the study in that member state.  
9.1.6  Submission of Summary of Clinical Study Report to Competent Authorities of 
Concerned Member States and IECs  
The Sponsor  will provide a summary of the Clinical Study Report within one year of the end of 
the complete trial to the competent authority of the concerned Member State(s) as required by 
[CONTACT_456057](s) and to comply with the Community guideline on Good Clinical 
practice. The Sponsor  will provide the IECs with a copy of the same summary.  
9.2 Investigator’s Responsibilities  
9.2.[ADDRESS_582927] undertake to perform the study in accordance with ICH GCP Guideline 
E614, EU Directive 2001/20/ EC17, and the applicable regulatory requirements. A copy of the 
guidelines will be available in the Investigator Site File.  
It is the Investigator’s responsibility to ensure that adequate time and appropriate resources 
are available at the study site prior to co mmitment to participate in this study. The Investigator 
should also be able to estimate or demonstrate a potential for recruiting the required number 
of suitable subjects within the agreed recruitment period.  
The Investigator will maintain a list of approp riately qualified persons to whom the Investigator 
has delegated significant trial -related tasks. An up -to-date copy of the curriculum vitae  for the 
Investigator, Sub-investigator(s) and essential study staff will be provided to the Sponsor  (or 
designee) b efore starting the study.  
If the subject has a primary physician the Investigator should, with the subject’s consent, inform 
them of the subject’s participation in the trial.  
A Coordinating Principal Investigator [INVESTIGATOR_456009], but prior to the end 
of the study,  to review the final Clinical Study Report for multicentre studies. Agreement with 
the final Clinical Study Report will be documented by [CONTACT_456058] (multicentre study), in compliance with Directive  
2001/83/EC  and ICH E3.18 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582928] or deviation from the protocol in the source 
documents and eCRFs or any other documents stipulated in the protocol.  
For investigational sites outside the EU, it is the Investigator’s responsibility t o communicate 
with their local IRB/IEC to ensure accurate and timely information is provided at all phases 
during the study; for investigational sites within the EU, this can be done by [CONTACT_1034] , the 
Investigator  or for multicentre studies the Coordinat ing Principal Investigator, according to 
national provisions. In particular the appropriate approvals must be in place prior to 
recruitment, notification of any SAEs during the study must take place and the IRB/IEC must 
be informed of study completion.  
9.2.3  Documentation and Retention of Records  
[IP_ADDRESS]  Case Report Forms  
Data for this study will be collected using electronic data capture (EDC). eCRFs  will be 
accessible via the internet for each subject’s study completion information.  
The Investigator is responsible for  maintaining adequate and accurate medical records from 
which accurate information will be transcribed onto eCRFs which have been designed to record 
all observations and other data pertinent to the clinical investigation. eCRFs  should be filled 
out complet ely by [CONTACT_456059] . 
Data must be entered into the eCRFs in English. All eCRFs must be completed in a timely 
manner and electronically submitted. The Principal Investigator [INVESTIGATOR_456010]. Laboratory reports must be reviewed, signed 
and dated by [CONTACT_456060].  
The eCRFs are to be completed as soon as possible from the time of the subject’s visit, with 
the exception of results of tests performed outside the Investigator’s office, so that they always 
reflect the latest observations on the subjects participating in the study.  
All eCRF corrections are to be made or reviewed by [CONTACT_456055].   
Completed eCRFs will be continuously submitted in the EDC system database, and reviewed 
by [CONTACT_456061]. Automatically generated queries will be 
answered by [CONTACT_456062].   
[IP_ADDRESS]  Recording, Access and Retention of Source Data  
Source data to be reviewed during this study will include, but is not limited to: subject’s medical 
file, subject diary cards, original laboratory reports, histology and pathology reports.  
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582929]’s medical records.  
The Investigator must permit authorised representatives of the Sponsor, the respective 
national, local or foreign regulatory authorities, the IRB/IEC, auditors and interested 
commercial parties to inspect facilities and original records relevant to this study.  
The monitor (auditors, IRB/IEC or regulatory inspectors) may check the CRF entries against 
the source documents. The consent form will include a statement by [CONTACT_456063]/auditor/inspector from the Sponsor  or its representatives, national or local 
regulatory authorities or the IRB/IEC access to source data (e .g., subject’s medical file, 
appointment books,  original laboratory reports, X -rays etc .) which substantiate information 
recorded in the CRFs. These personnel, bound by [CONTACT_56520], will not disclose any 
personal information or personal medication information.  
As described in the ICH GCP Guidelines, ‘essential documents’, including CRFs, source 
documents, consent forms, laboratory test results and investigational product  inventory 
records, should be retained by [CONTACT_31201] [ADDRESS_582930] be made available at reasonable times for inspection and duplication, if 
required, by a properly authorised representative of the US Food and Drug Administration 
(FDA) in accordance with the US Code of Federal Regulations 21 CFR 312.6819 or other 
national or foreign regulatory authorities  in accordance with regulatory requirements.  
[IP_ADDRESS]  Inves tigational Product Accountability  
All investigational product required for completion of this study will be provided by [CONTACT_1034] . 
The recipi[INVESTIGATOR_456011]. Damaged su pplies will be replaced. Accurate records of all 
investigational product dispensed, used and returned will be maintained.  
[IP_ADDRESS]  Audit/Inspection  
To ensure compliance with relevant regulations, data generated by [CONTACT_456064], for example, the US FDA (as well as other 
US national and local regulatory authorities), the [LOCATION_006] Medicines and Healthcare products 
Regulatory Agency (MHRA) and other foreign  regulatory authorities, the Sponsor  or its 
representat ives, interested commercial parties and the IRB/IEC for each study site.  
[IP_ADDRESS]  Financial Disclosure  
The Investigator will be required to disclose any financial arrangement whereby [CONTACT_456065]. 
The following information will be collected: any significant payments of other sorts from the 
Sponsor such as a grant to fund ongoing research, compensation in the form of equipment, 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 57 of 77 
 retainer for ongoing consultation or honoraria; any  proprietary interest in lubiprostone ; any 
significant equity interest in Sucampo Pharmaceuticals, Inc., or [COMPANY_005] Pharmaceuticals  as 
defined in 21 CFR 54 2(b).20 
In consideration of participation in the study, the Sponsor  will pay the Investigator or nominated 
payee the sums set out in the payment schedule attached to the Investigator agreement.  
9.3 Ethical Considerations  
The Investigator is responsible for ensuring that the clinical study is performed in accordance 
with the protocol, the note for Guidance on Good Clinical Practice ( Committee for Proprietary 
Medicinal Products /ICH/135/95 )21, and with applicable local regulatory requirements. These 
documents set forth that the informed consent of the subjects is an essential precondition for 
participation in the clinical study.  
9.3.1  Informed Consent  
It is the responsibility of the Investigator to  obtain written Informed Consent from subjects , or 
if under the age of consent, from their Legally Authorised Representative ( LAR; e.g., 
parent/legal guardian ). Assent should be obtained, in accordance with applicable local 
requirements, from minor subject s.  
All consent and assent documentation must be in accordance with applicable regulations and 
GCP. Each subject or the subject’s LAR, where applicable,  is requested to sign the IRB/IEC 
approved Subject Informed Consent Form after the subject /LAR  has recei ved and read the 
written subject information and received an explanation of what the study involves, including 
but not limited to: the objectives, potential benefits and risk, inconveniences and the subject’s 
rights and responsibilities. A copy of the info rmed consent documentation (Consent Form or 
Subject Information and the Consent/Assent Form, as applicable) must be given to the subject 
or the subject’s LAR.  
Informed consent documentation will be approved in the local language. If translation is 
require d into other languages, they must be certified and approved by [CONTACT_1201]/IEC for use. 
Signed consent/assent forms must remain in each subject’s study file and must be available 
for verification by [CONTACT_456066].  
For investigational sites outside  the EU, the Principal Investigator [INVESTIGATOR_456012] 
a copy of the IRB/IEC approved consent/assent forms, and a copy of the IRB/IEC’s written 
approval, prior to the start of the study. For investigational sites within the EU, submission and 
obtaining IEC approval of the informed consent documentation can be the responsibility of the 
Sponsor, the Investigator or for multi -centre studies the Coordinating Principal Investigator, 
according to national provisions. Additionally, if the IRB/IEC requir ed modification of the 
sample Subject Information and Consent/Assent document provided by [CONTACT_456], the 
documentation supporting this requirement must be provided to the sponsor.  
The sponsor reserves the right to delay initiation of the study at a site where the informed 
consent (and assent where applicable) forms do not meet the standards of applicable 
regulations and ICH GCP.  
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582931] or Independent Ethics Committee approval  
For investigational sites outside the EU, it is the responsi bility of the Investigator to submit this 
protocol, the informed consent /assent  document (approved by [CONTACT_456067]), 
relevant supporting information and all types of subject recruitment information to the IRB/IEC 
for review, and all must be  approved prior to site initiation . For investigational sites within the 
EU, the applicant for an IEC opi[INVESTIGATOR_169604] , the Investigator or for multi -centre 
studies the Coordinating Principal Investigator, according to national provisions. In add ition, 
advertisements must be approved by [CONTACT_1201]/IEC prior to use at the site. Prior to implementing 
changes in the study, the Sponsor  and the IRB/IEC must also approve any revised informed 
consent /assent  documents  and amendments to the protocol.  
On the approval letter, the trial (title, protocol number and version), the documents reviewed 
(protocol, informed consent material, [and amendments, if applicable])  and the date of review 
and actions taken should be clearly stated.  
Investigational product  supplies will not be released and the subject recruitment will not begin 
until this written approval has been received by [CONTACT_1034] . 
For investigational sites outside the EU, the Investigator is responsible for keepi[INVESTIGATOR_1683]/IEC 
appraised of the progr ess of the study and of any changes made to the protocol, but in any 
case at least once a year; for investigational sites within the EU, this can be done by [CONTACT_456068], according to national provisions. The Investigator must 
also keep the local IRB/IEC informed of any serious and significant adverse events.  
9.3.[ADDRESS_582932] s 
In consideration of the  responsibility to ensure that children are enrolled in clinical research 
that is both  scientifically necessary and ethically sound,22  the Sponsor has implemented the 
following measures to reduce the burden and stress of participation in this placebo -controlled 
trial: 
 Use of experienced Investigators and research personnel to appropriately  
assent/consent study participants. Site staff will be trained at an Investigator Meeting and 
at Site Initiation Visits;  
 Use of sparse PK sampling (population PK) to reduce the number of PK blood samples 
collected from each subject;  
 Minimization of clinic visit frequency for blood chemistry, haematology, and urinalysis 
collection during the study;  
 Minimization of cohorts of patients (to 6 -9 and 14 -17 year olds) to be subjected to DXA 
scans;  
 Allowing the use of protocol -specified rescue medication for the duration of the study;  
 Allowing for dose reduction in cases where subjects are experiencing specific adverse 
events;  and 
 Use of a DSMB for monitoring of safety for the duration of the study.  
 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582933] of 
1996 (HIPAA). An investigational site that is not a Covered Entity , as defined by [CONTACT_2373], must 
provide documenta tion of this fact to the Sponsor.  
Data collected during this study may be used to support the development, registration or 
marketing of lubiprostone. The Sponsor will control all data collected during the study, and will 
abide by [CONTACT_456069] P rivacy  (Directive 95/46/EC)  concerning the processing and 
use of subjects’ personal data. For the purpose of data privacy legislation, Sucampo Pharma 
Europe, Ltd.  will be the data controller.  
After subjects have consented to take part in the study their me dical records and the data 
collected during the study will be reviewed by [CONTACT_1052]/or its representatives. These 
records and data may, in addition, be reviewed by [CONTACT_716]: independent auditors who 
validate the data on behalf of the Sponsor; th ird parties with whom the Sponsor may develop, 
register or market lubiprostone; national or local regulatory authorities and the IRB(s)/IEC(s) 
which gave its/their approval for this study to proceed.  
Although subjects will be known by a unique number, thei r age and month and year  of birth 
will also be collected and used to assist the Sponsor to verify the accuracy of the data, for 
example, that the laboratory results are assigned to the correct subject. The results of this 
study containing the unique number , age, month and year  of birth and relevant medical 
information including ethnicity may be recorded and transferred to and used in other countries 
throughout the world, which may not afford the same level of protection that applies within the 
EU. The purpo se of any such transfer would be to support regulatory submissions made by 
[CONTACT_456070].  
9.[ADDRESS_582934] (FDAAA 801).  
 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 60 of 77 
 10. APPENDICES  
 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 62 of 77 
 [X will be equal to the other medicine  
selected in prior item response.]  
 
Did your child take this today or 
yesterday?  Today  
Yesterday  Observer only 
item 
X  
 
Please record the time of this dose.  [spi[INVESTIGATOR_456013]:xx]  Observer only 
item 
Confirm you would like  to report a  
Bowel Movement your child had today  
or yesterday:  
 
Today’s Date: DD Mon YYYY  
Yesterday’s Date: DD Mon YYYY  Yes 
No Observer only 
item 
Did this bowel movement occur today or 
yesterday ? Today  
Yesterday  Observer only 
item 
Please record the time of this bowel 
movement.  [spi[INVESTIGATOR_456013]:xx]  Observer only 
item 
Did your child have this bowel 
movement in the toilet?  Yes 
No 
I don't know  Observer only 
item 
Did the bowel movement clog the toilet?  Yes 
No 
I don't know  Observer only 
item 
Is your child with you right now and 
available  to answer questions about this 
bowel  movement?  Yes 
No Observer only 
item 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582935] week, how well did your 
child’s study medicine help?  0 – not at all effective  
1 – a little bit effective  
2 – moderately effective  
3 – quite a bit effective  
4 – extremely effective  Observer only 
item 
Over the past week, how many 
epi[INVESTIGATOR_456014]?  
 [continuous numeric; not applicable]  Observer only 
item  
 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 65 of 77 
 APPENDIX 2  PEDIATRIC BLOOD PRES SURE LEVELS  
 
 

Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 66 of 77 
  
 

Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 67 of 77 
  

Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 68 of 77 
  
 

Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 69 of 77 
 APPENDIX 3  PEDIATRIC HEART RATE  RANGES  
Normal Heart Rate Values for Age of Pediatric Patients*  
Age Heart Rate (bpm)  
Newborn  90-180 
1-5 months  100-180 
6-11 months  100-150 
1 year  100-150 
2-3 years  65-150 
4-5 years  65-140 
6-9 years  65-120 
10-12 years  65-120 
13 + years  55-110 
* Adapted from Silverman BK. Practical information In: Textbook of Pediatric Emergency Medicine 2006.24 
 
 
 
 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – 19 November 2015        Page 70 of 77 
 11. REFERENCES  
1. Baker SS, Liptak GS, Colletti RB, Croffie JM, Di Lorenzo C, Ector W, Nurko S. Constipation 
in infants and children : evaluation and treatment. A medical position statement of the North 
American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 
1999 Nov;29(5):612 –26. 
2. Biggs WS, Dery WH. Evaluation and treatment of constipation in infan ts and children. Am 
Fam Physician 2006 Feb;73(3):469 –77. 
3. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, Walker LS. 
Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006 
Apr;130(5):1527 –37. 
4. van den Berg MM, Benninga MA, Di Lorenzo C, et al. Epi[INVESTIGATOR_456015]: a systematic review. Am J Gastroenterology 2006;101:2401 –2409.  
5. van Ginkel R, Reitsma JB, Buller HA, et al. Childhood constipation: longitudinal  follow -up 
beyond puberty. Gas troenterology 2003;125:357 –363. 
6. Loening -Baucke V. Chronic constipation in children. Gastroenterology  1993;105:1557 –
1564.  
7. Staiano A, Andreotti MR, Greco L, et al. Long term follow -up of children with  chronic 
idiopathic constipation. Dig Di s Sci 1994;39:561 –564. 
8. van den Berg MM, van Rossum CH, de Lorijn F, et al. Functional constipation in infants: a 
follow -up study. J Pediatr 2005;147:700 –704. 
9. Bongers ME, Benninga MA, Maurice -Stam H, Grootenhuis MA. Health -related quality of life 
in young adults with symptoms of constipation continuing from childhood into adulthood. Health 
Qual Life Outcomes. 2009;7:20 . 
10. Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation 
and irritable bowel syndrome. Expert Op in Drug Saf. 2012 Sep;11(5):841 -50. 
11. Tucker ME. Lubiprostone provides capsule option for constipation in kids. Digestive 
Disorders. January 2010;52.  
12. Hyman PE, Di Lorenzo C, Prestidge LL, et al.. An open -label, multicentre, safety and 
effectiveness s tudy of lubiprostone for the treatment of functional constipation in children. J 
Pediatr Gastroenterol Nutr 2013; Sep 16. [Epub ahead of print].  
13. Varni, J.W., Seid, M., & Kurtin, P.S.  PedsQL  4.0: Reliability and validity of the Pediatric 
Quality of Li fe Inventory  Version 4.0 Generic Core Scales in healthy and patient populations.  
Medical Care  2001;  39:800-812. 
14. ICH GCP Guideline E6 – ICH Topic E6 (R1) Guideline for Good Clinical Practice.  
15. 21 CFR 312.32  – IND Safety Reports.  
16.  ICH Guid eline E1 – The Extent of Population Exposure to Assess Clinical Safety for Drugs 
Intended for Long -term Treatment of Non -life Threatening Conditions. 27 October 1994.  
17. Directive 2001/20/EC of the European Parliament and the Council on the approximation of 
the laws, regulations and administrative provisions of the Member States relating to the 
Sucampo AG  CONFIDENTIAL  
Protocol SAG/0211PFC -11S1    
 
Version 4.0 – [ADDRESS_582936] of clinical trials on medicinal products 
for human use. April 2001.  
18. ICH Guidance E3 – Structure and Content of  Clinical Study Reports.  
19. 21 CFR 312.68  – Inspection of Investigator’s Records and Reports.  
20. 21 CFR 54 2(b)  – Definitions ; Significant equity interest in the sponsor of a covered study . 
21. CPMP/ICH/135/95 - Note for Guidance on Good Clinical Practic e. 
22. Roth -Cline MD, Gerson J, Bright P, et al. Ethical considerations in conducting pediatric 
research. In Pediatric Clinical Pharmacology  2008 . 
23. Chumpi[INVESTIGATOR_456016].  Creation and initial evaluation of a stool form scale for children.  J 
Pediatr  2010;  October; 157(4): 594 –597. 
24. Silverman BK. Practical information In: Textbook of Pediatric Emergency Medicine 
2006.  
 
Sucampo AG   SAG/0211PFC -11S1-01 
 
 CONFIDENTIAL   [IP_ADDRESS]  Protocol Amendment Summaries  
 
 
LUBI PROSTONE: CLINICAL PROTOCOL   
SAG/0211PFC -11S1  
  
Protocol Amendment 3  CONFIDENTIAL  Page 73 of 77 
Summary of Changes; Version 1.0; 19 November 2015   Sucampo Pharma Americas, LLC . 
 Protocol SAG/0211PFC -11S1 Amendment 3 (Summary of changes)  
Date:  XX November 2015  
 
Protocol Version 4.0 will incorporate Amendment 3.  
 
The purpose of this amendment is to revise Protocol SAG/0211PFC -11S1 to reflect the following changes:  
     
LUBI PROSTONE : CLINICAL PROTOCOL   
SAG/0211PFC -11S1 
   
Protocol  Amendment 2 CONFIDENTIAL  Page 1 of 1 
Amendment Date : 10th December  2013  Sucampo AG Protocol SAG/0211PFC -11S1 Summary of changes for  
Amendment 2 
Date:  10 December  2013  
 
Protocol Version 3.0 will incorporate Amendment 2. 
 
The purpose of this amendment is to revise Protocol SAG/0211PFC -11S1 to reflect the 
following changes : 
 
Amendment 1 R evisions to Protocol SAG/0211PFC -11S1 
Page, Section  
Number , and Title   
Planned Revision s 
1 Page s 13-14, Protocol 
Synopsis, Objectives, Study 
Medication and Dose 
Regimen ; and  
Pages 21, Section 2.1 , 
Objectives  Previously:  To assess the long -term safety, efficacy, and pharmacokinetics of oral 
lubiprostone 12 or 24 mcg capsules dosed twice daily (BID) when administered orally for 
[ADDRESS_582937] s with functional constipation.  
 
Revised: To assess the long-term safety, efficacy, and pharmacokinetics of oral 
lubiprostone 12 or 24 mcg capsules dosed twice daily (BID) when administered orally for 36 weeks in paediatric subjects with functional constipation. Evaluation of lubiprostone 
safety is the primary objective  of this study . 
2 Page s 13-14, Protocol 
Synopsis, Safety 
Evaluation/Efficacy Evaluation; 
Page 21-22, Section 2.2 , 
Endpoints ; and  
Pages 49-53, Sections 8.5 and 
8.6 Previously:  Efficacy endpoints were presented before safety endpoints . 
 
Revised: Safety endpoints are now presented before efficacy endpoints.  
 
 
     
LUBI PROSTONE : CLINICAL PROTOCOL   
SAG/0211PFC -11S1 
   
Protocol SAG/0211PFC -11S1 Summary of changes for  
Amendment 1 
Date:  26 November  2013  
 
Protocol Version 2.0 will incorporate Amendment 1. 
 
The purpose of this amendment is to revise Protocol SAG/0211PFC -11S1 to reflect the 
following changes : 
 
Amendment 1 Revisions to Protocol SAG/0211PFC -11S1 
Page, Section  
Number , and Title   
Planned Revision s 
1 Page 1 3, Protocol Synopsis, 
Exclusion  Criteria Number 5 
and 
Page 26 , Section 4. 2, 
Exclusion Criteria Number 5 Previously:  Subject (female of childbearing potentia l) has a positive pregnancy test, or 
refuses/unwilling to undergo pregnancy testing. 
 
Revised: Subject (female of childbearing potential) has a positive pregnancy test, 
refuses/unwilling to undergo pregnancy testing, and/or does not agree to use protocol -
specified contraceptive measures for the duration of the study.  
 
2 Page 26, Section 4. 4, 
Contraception Specifications  
 Added  New Section : Female subjects of child -bearing potential must agree to remain 
abstinent or to use adequate contraception during study participation. The type of 
contraception being used by [CONTACT_456071] . 
Adequate contraception is defined as use of any of the following:  
• Oral Contraceptives– must have been used for at least 3 months prior to the 
Screening Visit (Visit 1) ; 
• Intrauterine Device (IUD) ; or 
• Double barrier method. 
 
3 Section 6.1, Study Procedures 
by [CONTACT_4838] (specifically Page 35, 
Section 6.1.2; Page 36, Section 
6.1.3 .1; Page 37, Section 
6.1.3 .3; Page 38, Section 
6.1.3 .4; and Page 39, Sectio n 
6.1.4. 1) Added total blood volume to be collected at each relevant study visit for clinical 
laboratory and pharmacokinetic (PK) analyses, as follows:  
 Visit 9: 5.5 mL for clinical laboratory samples and 16 mL for  PK samples  
Randomization visit (Visit 2): 16 mL  
Visits 10, 12, 14, 16, and 17: 5.5 mL  
 
4 Page 59, Section 9.3.3, 
Measures for Reduction of Stress and Pain in Pediatric Patients  
 Added New Section : In consideration of the responsibility to ensure that children are 
enrolled in clinical research that is both scientifically necessary and ethically sound,22  the 
Sponsor has implemented the following measures to reduce the burden and stress of participation in this placebo- controlled trial:  
• Use of experienced Investigators and research personnel to appropriately 
assent/consent study participants. Site staff will be trained at an Investigator Meeting 
and at Site Initiation Visits;  
• Use of sparse PK sampling (population PK) to reduce the number of PK blood samples collected from each subject;  
• Minimizatio n of regular blood chemistry, haematology, and urinalysis collection during 
the study (optional collection given at Week 8 visit);  
• Allowing the use of protocol -specified rescue medication for the duration of the study;  
• Allowing for dose reduction in cases where subjects are experiencing specific 
adverse events; and  
• Use of a DSMB for monitoring of safety for the duration of the study.  
  
22 Roth -Cline MD, Gerson J, Bright P, et al. Ethical considerations in conducting pediatric 
research. In Pediatric Clinical  Pharmacology , 2008.  
 
Protocol  Amendment 1 CONFIDENTIAL  Page 1 of 1 
Amendment Date : 26 November 2013  Sucampo Pharma  Americas , LLC. 